
<html lang="en"     class="pb-page"  data-request-id="6e18e81c-22a5-4889-8e9b-cccf8307e587"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm5018169;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2015.58.issue-4"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors" /></meta><meta name="dc.Creator" content="J. Michael  Ellis" /></meta><meta name="dc.Creator" content="Michael D.  Altman" /></meta><meta name="dc.Creator" content="Alan  Bass" /></meta><meta name="dc.Creator" content="John W.  Butcher" /></meta><meta name="dc.Creator" content="Alan J.  Byford" /></meta><meta name="dc.Creator" content="Anthony  Donofrio" /></meta><meta name="dc.Creator" content="Sheila  Galloway" /></meta><meta name="dc.Creator" content="Andrew M.  Haidle" /></meta><meta name="dc.Creator" content="James  Jewell" /></meta><meta name="dc.Creator" content="Nancy  Kelly" /></meta><meta name="dc.Creator" content="Erica K.  Leccese" /></meta><meta name="dc.Creator" content="Sandra  Lee" /></meta><meta name="dc.Creator" content="Matthew  Maddess" /></meta><meta name="dc.Creator" content="J. Richard  Miller" /></meta><meta name="dc.Creator" content="Lily Y.  Moy" /></meta><meta name="dc.Creator" content="Ekundayo  Osimboni" /></meta><meta name="dc.Creator" content="Ryan D.  Otte" /></meta><meta name="dc.Creator" content="M. Vijay  Reddy" /></meta><meta name="dc.Creator" content="Kerrie  Spencer" /></meta><meta name="dc.Creator" content="Binyuan  Sun" /></meta><meta name="dc.Creator" content="Stella H.  Vincent" /></meta><meta name="dc.Creator" content="Gwendolyn J.  Ward" /></meta><meta name="dc.Creator" content="Grace H. C.  Woo" /></meta><meta name="dc.Creator" content="Chiming  Yang" /></meta><meta name="dc.Creator" content="Hani  Houshyar" /></meta><meta name="dc.Creator" content="Alan B.  Northrup" /></meta><meta name="dc.Description" content="Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographi..." /></meta><meta name="Description" content="Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 16, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm5018169" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm5018169" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm5018169" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm5018169" /></link>
        
    
    

<title>Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm5018169" /></meta><meta property="og:title" content="Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0021.jpeg" /></meta><meta property="og:description" content="Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand binding efficiency. Attenuation of hERG ion channel activity inherent within the initial chemotype was guided through modulation of physicochemical properties including log D, PSA, and pKa. PSA proved most effective for prospective compound design. Further profiling of an advanced compound revealed bacterial mutagenicity in the Ames test using TA97a Salmonella strain, and subsequent study demonstrated that this mutagenicity was pervasive throughout the series. Identification of intercalation as a likely mechanism for the mutagenicity-enabled modification of the core scaffold. Implementation of a DNA binding assay as a prescreen and models in DNA allowed resolution of the mutagenicity risk, affording molecules with favorable potency, selectivity, pharmacokinetic, and off-target profiles." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand binding efficiency. Attenuation of hERG ion channel activity inherent within the initial chemotype was guided through modulation of physicochemical properties including log D, PSA, and pKa. PSA proved most effective for prospective compound design. Further profiling of an advanced compound revealed bacterial mutagenicity in the Ames test using TA97a Salmonella strain, and subsequent study demonstrated that this mutagenicity was pervasive throughout the series. Identification of intercalation as a likely mechanism for the mutagenicity-enabled modification of the core scaffold. Implementation of a DNA binding assay as a prescreen and models in DNA allowed resolution of the mutagenicity risk, affording molecules with favorable potency, selectivity, pharmacokinetic, and off-target profiles." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0021.jpeg" /></meta><meta name="twitter:title" content="Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm5018169"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm5018169">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm5018169&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm5018169&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm5018169&amp;href=/doi/10.1021/jm5018169" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1929-1939</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm501799k" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm5018303" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Michael++Ellis">J. Michael Ellis</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Altman">Michael D. Altman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan++Bass">Alan Bass</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+W.++Butcher">John W. Butcher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan+J.++Byford">Alan J. Byford</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony++Donofrio">Anthony Donofrio</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheila++Galloway">Sheila Galloway</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+M.++Haidle">Andrew M. Haidle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Jewell">James Jewell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nancy++Kelly">Nancy Kelly</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Erica+K.++Leccese">Erica K. Leccese</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Lee">Sandra Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Maddess">Matthew Maddess</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Richard++Miller">J. Richard Miller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lily+Y.++Moy">Lily Y. Moy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ekundayo++Osimboni">Ekundayo Osimboni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ryan+D.++Otte">Ryan D. Otte</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=M.+Vijay++Reddy">M. Vijay Reddy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kerrie++Spencer">Kerrie Spencer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Binyuan++Sun">Binyuan Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stella+H.++Vincent">Stella H. Vincent</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gwendolyn+J.++Ward">Gwendolyn J. Ward</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Grace+H.+C.++Woo">Grace H. C. Woo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chiming++Yang">Chiming Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▽</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hani++Houshyar">Hani Houshyar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan+B.++Northrup">Alan B. Northrup</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Department of Discovery Chemistry, <sup>‡</sup>Department of Process Research, <sup>§</sup>Department of Immunology, <sup>∥</sup>Department of Pharmacology, <sup>⊥</sup>Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, <sup>#</sup>Department of Safety Assessment and Laboratory Animal Resources, and <sup>▽</sup>Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +1-617-992-3144; e-mail: <a href="/cdn-cgi/l/email-protection#1974707a71787c75467c7575706a59747c6b7a72377a7674"><span class="__cf_email__" data-cfemail="462b2f252e27232a19232a2a2f35062b2334252d6825292b">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm5018169&amp;href=/doi/10.1021%2Fjm5018169" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1929–1939</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 27, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 November 2014</li><li><span class="item_label"><b>Published</b> online</span>16 February 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 February 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm5018169" title="DOI URL">https://doi.org/10.1021/jm5018169</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1929%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJ.%2BMichael%2BEllis%252C%2BMichael%2BD.%2BAltman%252C%2BAlan%2BBass%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D4%26contentID%3Djm5018169%26title%3DOvercoming%2BMutagenicity%2Band%2BIon%2BChannel%2BActivity%253A%2BOptimization%2Bof%2BSelective%2BSpleen%2BTyrosine%2BKinase%2BInhibitors%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1939%26publicationDate%3DFebruary%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm5018169"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3049</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm5018169" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Michael Ellis&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Altman&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Bass&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;W. Butcher&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;J. Byford&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;Donofrio&quot;},{&quot;first_name&quot;:&quot;Sheila&quot;,&quot;last_name&quot;:&quot;Galloway&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;M. Haidle&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Jewell&quot;},{&quot;first_name&quot;:&quot;Nancy&quot;,&quot;last_name&quot;:&quot;Kelly&quot;},{&quot;first_name&quot;:&quot;Erica&quot;,&quot;last_name&quot;:&quot;K. Leccese&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Maddess&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Richard Miller&quot;},{&quot;first_name&quot;:&quot;Lily&quot;,&quot;last_name&quot;:&quot;Y. Moy&quot;},{&quot;first_name&quot;:&quot;Ekundayo&quot;,&quot;last_name&quot;:&quot;Osimboni&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;D. Otte&quot;},{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Vijay Reddy&quot;},{&quot;first_name&quot;:&quot;Kerrie&quot;,&quot;last_name&quot;:&quot;Spencer&quot;},{&quot;first_name&quot;:&quot;Binyuan&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Stella&quot;,&quot;last_name&quot;:&quot;H. Vincent&quot;},{&quot;first_name&quot;:&quot;Gwendolyn&quot;,&quot;last_name&quot;:&quot;J. Ward&quot;},{&quot;first_name&quot;:&quot;Grace&quot;,&quot;last_name&quot;:&quot;H. C. Woo&quot;},{&quot;first_name&quot;:&quot;Chiming&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Hani&quot;,&quot;last_name&quot;:&quot;Houshyar&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;B. Northrup&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;1929-1939&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm5018169&quot;},&quot;abstract&quot;:&quot;Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand binding efficiency. Attenuation of hERG ion channel activity inherent within the initial chemotype was guided through modulation of physicochemical properties including log D, PSA, and pKa. PSA proved most effective for prospective compound design. Further profiling of an advanced compound revealed bacterial mutagenicity in the Ames test using TA97a Salmonella strain, and subsequent study demonstrated that this mutagenicity was pervasive throughout the series. Identification of intercalation as a likely mechanism for the mutagenicity-enabled modification of the core scaffold. Implementation of a DNA binding assay as a prescreen and models in DNA allowed resolution of the mutagenicity risk, affording molecules with favorab&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5018169&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5018169" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5018169&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5018169" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5018169&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5018169" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm5018169&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5018169&amp;href=/doi/10.1021/jm5018169" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm5018169" /></input><a href="/doi/pdf/10.1021/jm5018169" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm5018169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm5018169%26sid%3Dliteratum%253Aachs%26pmid%3D25625541%26genre%3Darticle%26aulast%3DEllis%26date%3D2015%26atitle%3DOvercoming%2BMutagenicity%2Band%2BIon%2BChannel%2BActivity%253A%2BOptimization%2Bof%2BSelective%2BSpleen%2BTyrosine%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D4%26spage%3D1929%26epage%3D1939%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a>,</li><li><a href="/action/doSearch?ConceptID=290667" title="Ions">Ions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/4" title="Go to Volume 58, Issue 4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jmcmar.2015.58.issue-4/20150226/jmcmar.2015.58.issue-4.largecover.jpg" alt="Go to Volume 58, Issue 4"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand binding efficiency. Attenuation of hERG ion channel activity inherent within the initial chemotype was guided through modulation of physicochemical properties including log <i>D</i>, PSA, and p<i>K</i><sub>a</sub>. PSA proved most effective for prospective compound design. Further profiling of an advanced compound revealed bacterial mutagenicity in the Ames test using TA97a <i>Salmonella</i> strain, and subsequent study demonstrated that this mutagenicity was pervasive throughout the series. Identification of intercalation as a likely mechanism for the mutagenicity-enabled modification of the core scaffold. Implementation of a DNA binding assay as a prescreen and models in DNA allowed resolution of the mutagenicity risk, affording molecules with favorable potency, selectivity, pharmacokinetic, and off-target profiles.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60133" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60133" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The utility of kinase inhibitors in treating oncological disorders was affirmed by the approval of imatinib in 2001.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In recent years, small molecule inhibitors of protein kinases have been examined for use in various autoimmune disorders, including rheumatoid arthritis (RA).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> RA is a systemic inflammatory disorder that affects ∼1% of the worldwide population, with women three times more likely than men to develop the disease.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Disease progression is characterized by synovial hyperplasia, inflammation, and irreversible joint destruction. This commonly leads to disability and consequent reduction in the quality of life and, if untreated, reduces life expectancy in patients. The pathogenesis of RA consists of a cascade of pro-inflammatory cytokines and chemokines leading to the recruitment of inflammatory cells. Traditionally, T cells, macrophages, neutrophils, and synovial fibroblasts were thought to be associated with RA;<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> however, current evidence suggests that autoreactive B cells, immune complexes, osteoclasts, mast cells, and basophils also contribute to the disease.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Current therapies used to treat RA generally fall into two broad categories: palliative therapies and disease-modifying agents. Palliative therapies are prescribed to provide symptomatic relief from the pain and inflammation characteristic of RA. Disease-modifying therapies including conventional disease-modifying antirheumatic drugs (DMARDs) and biologic agents are prescribed to halt the destructive course of RA and prevent debilitating joint damage. Despite their success, the use of conventional DMARDs and biologics is limited by nonresponse in a subset of patients, safety concerns, and the high cost and discomfort of continuous injections with biologics. The 2012 approval of tofacitinib, an oral pan-Janus kinase (JAK) inhibitor, for treatment of RA cases that are inadequately responsive to methotrexate provides proof of concept for the therapeutic approach of kinase inhibition for the treatment of RA.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Spleen tyrosine kinase (Syk) is a key enzyme involved in Fc and B cell receptor (BCR) signaling in multiple cell types involved in the immune response.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Inhibition of Syk activity is expected to slow the destructive course of RA by affecting the initiation phase via modulation of signaling downstream of the BCR, the effector phase via blockade of the Fc receptors (FcεR, FCγR) in various immune cells in the synovium, and the ensuing tissue damage via inhibition of osteoclast maturation.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Multiple preclinical studies have shown that genetic depletion of Syk or inhibition of Syk with small molecule inhibitors (including published R788 (<b>1</b>), PRT-062607 (<b>2</b>), RO9021 (<b>3</b>), and GS-9973 (<b>4</b>)) attenuates inflammation, tissue damage and bone destruction in preclinical RA models (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9-12)</a> Human proof-of-concept has been achieved in RA clinical trials with the poorly selective oral Syk inhibitor <b>1</b> (52% of 100 kinases tested >100× Syk IC<sub>50</sub>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Additional human proof-of-biology has been established with the B-cell depletion therapy Rituximab, approved for the treatment of RA.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Dosing with <b>1</b> in humans was limited by hypertension and diarrhea as the most common adverse events. We hypothesized that the hypertension observed was driven by off-target activity<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and sought to develop a selective Syk inhibitor for the treatment of various autoimmune and hematological diseases, including RA, oncology,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> and asthma,<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> devoid of this undesired pharmacology. This manuscript describes the preparation of diaminocarboxamides that are highly selective, potent Syk inhibitors, and details regarding the attenuation of inherent hERG ion channel activity and mutagenicity risk within the chemotype to ultimately afford novel Syk inhibitors with favorable overall profiles.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Diverse Syk inhibitor motifs from the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The two main points of structure–activity relationship diversity for the aminodipyridylcarboxamides were in the basic amine region and the aminoheterocycle (solvent front) region. We developed modular approaches allowing late stage introduction of each of these functionalities (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Namely, the basic amine portion of the molecule could be introduced, first starting from a dihalopyridyl nitrile under S<sub>N</sub>Ar or palladium-mediated conditions. As an example of the former method, the synthesis of picolinamide <b>5</b> commenced via reaction of 3-bromo-5-fluoropyridine-2-carbonitrile (<b>6</b>) and <i>tert</i>-butyl [(1<i>S</i>,2<i>R</i>)-2-aminocyclohexyl]carbamate mediated by base to afford bromide <b>7</b> in 82% yield. Introduction of 2-amino-4,6-dimethylpyridine was accomplished under Buchwald–Hartwig conditions in high yield.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Alkaline peroxide promoted the hydrolysis of nitrile <b>8</b> to the corresponding amide, which was subsequently deprotected under acidic conditions and free-based with ammonia in methanol to provide carboxamide <b>5</b> in 84% yield over three steps.</div><div class="NLM_p">Alternatively, picolinamide <b>9</b> was prepared using the latter method of early stage aminoheterocycle introduction (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Anionic addition of 4,6-dimethylpyridin-2-amine to 5-bromo-3-fluoropicolinonitrile (<b>10</b>) gave bromopyridine <b>11</b>. Palladium-mediated coupling of <i>tert</i>-butyl (1-(aminomethyl)cyclopropyl)carbamate gave diaminopyridine <b>12</b>, which was further functionalized via acidic deprotection and hydrolysis to afford carboxamide <b>9</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i>-Linked Heterocycles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) <i>tert</i>-Butyl [(1<i>S</i>,2<i>R</i>)-2-aminocyclohexyl]carbamate, DIEA, 110 °C; (b) 2-amino-4,6-dimethylpyridine, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C; (c) NaOH, 35% aq H<sub>2</sub>O<sub>2</sub>, DMSO, rt; (d) HCl, dioxane; (e) NH<sub>3</sub>, MeOH, rt.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Alternative Approach to the Synthesis of <i>N</i>-Linked Heterocycles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 2-Amino-4,6-dimethylpyridine, KO-<i>t</i>-Bu, THF, 0 °C; (b) <i>tert</i>-butyl (1-(aminomethyl)cyclopropyl)carbamate, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt (d) NaOH, 35% aq H<sub>2</sub>O<sub>2</sub>, DMSO, rt.</p></p></figure><div class="NLM_p">For the later generation <i>C</i>-linked carboxamides, a modified synthetic approach was employed. As an exemplar, preparation of <b>13</b> commenced via S<sub>N</sub>Ar addition of <i>tert</i>-butyl ((1<i>S</i>,2<i>R</i>)-2-aminocyclohexyl)carbamate and 2,6-dichloropyrazine (<b>14</b>) to give chloropyrazine <b>15</b> in 88% yield (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Iodination para to the newly installed amine was accomplished using <i>N</i>-iodosuccinimide to afford dihalopyrazine <b>16</b> in 91% yield. Carefully monitored cyanation under palladium-mediated conditions provided nitrile <b>17</b> in 83% yield, which was subsequently functionalized via a Suzuki–Miyaura coupling to install the indole moiety.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Deprotection and hydrolysis of the nitrile <b>18</b> delivered carboxamide <b>13</b> in 48% yield over three steps.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <i>C</i>-Linked Heterocycles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) <i>tert</i>-Butyl [(1<i>S</i>,2<i>R</i>)-2-aminocyclohexyl]carbamate, DIEA, 115 °C; (b) NIS, DMF, 65 °C; (c) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 120 °C; (d) 1<i>H</i>-indole-2-boronic acid pinacol ester, Pd(OAc)<sub>2</sub>, PCy<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, THF, 65 °C; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) KOH, 35% aq H<sub>2</sub>O<sub>2</sub>, DMSO, rt.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our primary medicinal chemistry goal was to identify a highly kinome-selective molecule that demonstrated favorable properties for further development activities. Carboxamide scaffolds (e.g., PRT-062607) were known in the literature at the outset of our efforts as potent Syk inhibitors. Examining the available structural and crystallographic data for Syk revealed Asp-512 as a key residue to target for selectivity enhancement.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Namely, an appropriately positioned array of hydrogen bond donors, such as the diamine present in YM-70220, had been demonstrated to recruit Asp-512 toward the ATP site, affording improved kinome selectivity, as this motion of the catalytic Asp is unfavorable for a number of kinases (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Having settled upon Asp-512 as a key point of interaction, we next undertook a systematic core scan of diaminocarboxamides (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Our objective was to ensure a high ligand efficiency for Syk, while obviating the presence of a potentially reactive aniline substructure, which has been reported to increase risk for toxicity.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Generally, ligand efficiencies were in an acceptable range for all permutations tested (0.42–0.56); structure–activity relationships revealed that aryl carboxamides possessing nitrogen ortho to the carboxamide were beneficial to potency (picolinamide <b>5</b> vs benzamide <b>19</b>), while a nitrogen at the meta position was deleterious to potency (benzamide <b>19</b> vs nicotinamide <b>20</b>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> We hypothesized that an intramolecular hydrogen bond between the amide NH and the heteroaryl nitrogen served to preorganize the ground-state conformation in a planar geometry stabilizing the bioactive conformation as well as lower the penalty for desolvation (<b>23</b> versus <b>24</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). In contrast, an antagonistic steric interaction between the NH of the amide and the CH ortho to the amide is present in chemotypes lacking this heteroaryl nitrogen. Further, we proposed that the <i>m</i>-nitrogen present in nicotinamide <b>20</b> and pyridazinecarboxamide <b>21</b> favors a ground-state diamine conformation that requires a 180° rotation for recruitment of Asp-512 in the bioactive conformation (<b>25</b> versus <b>26</b>). Picolinamide <b>22</b> demonstrated an antagonistic interaction between the aniline solvent front and the picolinamide core resulting in a 100-fold intrinsic potency loss versus picolinamide <b>5</b> (<b>27</b> versus <b>28</b>). The potency advantage of the aminodipyridine was aligned with our strategy to avoid anilines. With this data set, we chose to focus our efforts on the 3,5-diaminopicolinamides represented by compound <b>5</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Carboxamide Core Scan: Enzyme Potency and Ligand Binding Efficiency (LBE)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0015.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">See ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</p></div></div><div></div></div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Rationale for intrinsic potency differences across cores.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Interaction of basic amine with Asp-512 for Syk potency and selectivity. X-ray cocrystal structure of YM-70220 in Syk (yellow) overlayed with AMP-PMP structure with Syk (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further profiling of representative 3,5-diaminopicolinamide <b>5</b> revealed a number of favorable aspects; high enzymatic (Syk IC<sub>50</sub> = 60 pM) and human whole blood potency (hWB CysLT IC<sub>50</sub> = 58 nM) had been achieved, along with exquisite kinome selectivity (100% of 265 kinases tested >100× Syk IC<sub>50</sub>). Carboxamide <b>5</b> also demonstrated high enzymatic selectivity versus the homologous enzyme zeta-chain-associated protein kinase 70 (Zap70) with an IC<sub>50</sub> of 5.3 nM (Zap70 IC<sub>50</sub>/Syk IC<sub>50</sub> = 90×).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Further, the physicochemical properties (HPLC log <i>D</i> = 2.1, PSA = 118) and oral pharmacokinetic profile (rat plasma Cl<sub>p</sub> (Cl<sub>u</sub>) = 33 (710) mL/min/kg, rat <i>T</i><sub>1/2</sub> = 2.7 h, F = 19%) of this molecule were in a desirable range.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Picolinamide <b>5</b> was profiled in the rat collagen-induced arthritis model and demonstrated therapeutic efficacy at doses as low as 3 mg/kg QD PO (<i>C</i><sub>max</sub> = 0.2 μM, <i>C</i><sub>min</sub> = 0.007 μM, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). However, a key off-target activity of compound <b>5</b> was inhibition of the human ether-a-go-go related gene (hERG, <i>I</i><sub>Kr</sub> IC<sub>50</sub> = 1.6 μM). Several strategies have proven effective in the medicinal chemistry literature for attenuating delayed rectifying potassium channel activity including modulation of basicity and polarity.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> We targeted the diamine and aminoheterocycle directed toward the solvent front for modification in an attempt to merge the favorable properties of carboxamide <b>5</b> with weaker ion channel activity.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Rat collagen-induced arthritis efficacy of 3,5-diaminopicolinamide <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> details a systematic survey of the diamine portion of the molecules while holding the 2-amino-4,6-dimethylpyridine constant. A number of calculated and measured properties were then leveraged to examine correlations between each category of properties and the corresponding hERG ion channel activities. A good correlation has been established in the literature and was recapitulated with these chemotypes, between an automated patch clamp system, PatchXpress, and a higher throughput binding assay for measuring or estimating <i>I</i><sub>Kr</sub> IC<sub>50</sub> values.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> It is well-precedented that attenuation of amine basicity can result in weaker delayed rectifying potassium channel binding.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> To maintain good Syk potency, it was important to avoid rendering the diamine nonbasic at physiological pH (e.g., <b>29</b> and <b>33</b>). Calculated and/or measured p<i>K</i><sub>a</sub>’s above 7.0 showed little to no correlation with ion channel activity as measured via PatchXpress (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). There was also a lack of correlation between measured HPLC log <i>D</i> and <i>I</i><sub>Kr</sub> activity within a log <i>D</i> range of 0.7 and 2.3, though it did trend slightly in the expected direction with more polar molecules showing lower ion channel binding (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The most robust correlation was found between polar surface area (PSA) and hERG ion channel activity, as a higher PSA biased molecules toward weaker activity, while maintaining Syk potency (<b>32</b>). The diaminotetrahydrothiopyran dioxide identified from this survey and exemplified in picolinamide <b>32</b> emerged as a preferred moiety for interacting with Asp-512 while maintaining potency (Syk IC<sub>50</sub> = 0.1 nM), kinome selectivity (100% of kinases >100×, 265 kinases tested), and an improved off-target profile (hERG, <i>I</i><sub>Kr</sub> IC<sub>50</sub> = 29 μM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Amine Region hERG Ion Channel SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0016.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0017.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Polar surface area.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Calculated p<i>K</i><sub>a</sub>.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">MK-499 displacement IC<sub>50</sub> (μM).</p></div></div><div></div></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Physicochemical properties versus hERG ion channel activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Efforts were next directed toward examining the impact of the aminoheterocycle directed toward the solvent front on hERG ion channel activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). In this case, the cyclohexyldiamino group was held constant to ensure a sufficient dynamic range for assessing the impact of the heterocycle. Again, polarity emerged as the key driver, as both measured HPLC log <i>D</i> and calculated PSA demonstrated strong correlations with hERG interaction (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Namely, lower HPLC log <i>D</i> (<1.0) and higher PSA (>145) effectively ablated potent <i>I</i><sub>Kr</sub> activity in the absence of attenuated diamine basicity. Having demonstrated the impacts of PSA across two distinct portions of the molecules on ion hERG activity, planning of future molecules was guided by calculation of this physicochemical property. This prospective analysis allowed rapid triage and prioritization of novel inhibitor designs. In short order, picolinamide <b>42</b> was synthesized and demonstrated a favorable overall profile (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). Carboxamide <b>42</b> was a potent and selective Syk inhibitor (Syk IC<sub>50</sub> = 0.6 nM, 99% of kinases >100×, 265 kinases tested, BLK IC<sub>50</sub> = 32 nM, ROS IC<sub>50</sub> = 43 nM) that demonstrated good cell and functional activity (hWB CysLT IC<sub>50</sub> = 56 nM) lacking the ion channel activity of previous prototypes (hERG, <i>I</i><sub>Kr</sub> IC<sub>50</sub> >30 μM). Though <b>42</b> has a higher calculated PSA (PSA = 167) than many druglike molecules (typically PSA ≤140 for oral bioavailability), a favorable pharmacokinetic profile in preclinical species was obtained, including oral exposure (rat plasma Cl<sub>p</sub> (Cl<sub>u</sub>) = 19 (270) mL/min/kg, rat <i>T</i><sub>1/2</sub> = 2.8 h, 30% F). The calculated PSA is believed to be an overestimate due to the extensive intramolecular hydrogen bonding network within the ground state of the molecule that serves to mask some of the inherent polarity from a topological assessment.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Solvent Front hERG Ion Channel SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0018.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0019.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Polar surface area.</p></div></div><div></div></div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Physicochemical properties versus hERG ion channel activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Profile of picolinamide <b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While preparing carboxamide <b>42</b> to move toward development, a report appeared in the literature of mutagenicity in the bacterial reverse mutation (Ames) test for a molecule of a similar chemotype, GSK-143 (<b>43</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The report described a positive Ames test result for pyrimidinecarboxamide <b>43</b> in <i>Salmonella typhimurium</i> strain TA1537 without metabolic activation (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Mutation in this strain often reflects intercalation of the test molecule into DNA, and such activity can also be detected in <i>Salmonella</i> strains TA97 and TA97a, which are considered equally acceptable with TA1537 under international test guidelines.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Since TA97a is the strain we use routinely, we selected this strain when carrying out a minimal screen and performed the mutation testing in the presence of rat S9 because the mutagenicity of <b>43</b> and some other candidates was enhanced by S9 in our hands, and potential mutagenicity of aromatic amine metabolites (see below) would require metabolic activation. Our lead compound <b>42</b> induced mutation in strain TA97a in the presence of rat S9. Similarly, picolinamide <b>5</b> was tested and showed a positive result at ≥300 μg/plate. Speculating that a metabolite could be the culprit in these results, we prepared and tested two potential degradative products. Diaminopyridine <b>45</b> had been found as a <i>N</i>-dealkylative metabolite in rat and human hepatocyte MetID studies. This molecule was predicted by DEREK for Windows (version 12.5.4, Lhasa Ltd., Leeds, UK) and Multi-CASE (MC4PC version 2.3.0.15, Multi-CASE Inc., Cleveland, OH) to be positive in the Ames test due to the known mutagenic substructure of the primary aromatic amine in <b>45</b> (anilines <b>46</b> and <b>47</b> are known Ames-positive compounds that feature this motif). However, the assay in strain TA97a was negative for <b>45</b> up to 3000 μg/plate with rat S9. Tricycle <b>44</b> had been observed to form upon standing with acid and could have been a prime suspect for intercalation. However, this compound was also negative in in TA97a with S9 up to 3000 μg/plate. With these results in hand, we began to formulate hypotheses to overcome the putative intercalation liability within this series.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Initial compounds for mutagenicity assessment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Leveraging DNA cocrystals with acridine, a docking model was developed for our Syk inhibitors (represented by picolinamide <b>5</b>) in DNA (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This model revealed three distinct opportunities to disrupt DNA intercalation with our molecules. Namely, reducing the basicity of the amine functionality should disfavor the donation of hydrogen bonds to the DNA carbonyl. Second, growing toward, or shrinking from, the DNA backbone was predicted to disrupt the fit of our small molecules in DNA, leading to a less thermodynamically favorable interaction. Finally, introducing three-dimensionality could serve to disfavor the stabilizing π-stack with DNA, mitigating the intercalation liability. We set out to test each of these hypotheses. Cognizant of the possibility that general cytotoxicity of molecules could confound comparisons across results from the mutagenicity assay, we also sought to develop an orthogonal higher throughput in vitro assay specific for DNA interaction.</div><div class="NLM_p">We observed that the UV–vis spectrum of some carboxamide compounds showed a saturable perturbation upon addition of duplex DNA, as reported for other organic ligands.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This facile assay allowed inhibitors to be tested prior to, or concurrent with, the TA97a mutagenicity assay, although the metabolic activation system (S9) were not incorporated into the DNA interaction assay. To validate this approach, picolinamides <b>5</b> and <b>42</b> were profiled, and each showed positive data for DNA interaction, consistent with the mutagenicity results.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Further, metabolite <b>45</b> was negative in the UV–vis assay, again matching the mutagenicity results for this compound.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Of note, tricycle <b>44</b>, which was negative in the TA97a mutagenicity, was positive for DNA interaction in the UV–vis assay. Thus, the UV–vis assay can give false positive results compared with the bacterial mutagenicity assay in TA97a (though the results may be more robust, since cytotoxicity is not a confounder in this model), but we never observed a false negative in this assay,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> supporting its use as an orthogonal assessment of intercalation risk and serving as a stage-gate for the lower throughput bacterial mutagenicity assay.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Docking model of picolinamide <b>5</b> in DNA (from acridine/DNA cocrystals).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, our first hypothesis regarding the attenuation of basicity still afforded mutagenic/UV–vis positive compounds (e.g., compound <b>48</b>). Ablating the basicity completely, as in carboxamide <b>49</b>, afforded compounds predicted to lack intercalation but at the expense of Syk activity (Syk IC<sub>50</sub> = 60 nM). As previously detailed, the basic amine interaction of our carboxamide inhibitors with Asp-512 is a critical element for potency and selectivity on the enzyme.</div><div class="NLM_p">We next systematically surveyed substitution at the 4-, 5-, and 6-positions of the aminopyridine projected toward solvent. Examples <b>50</b>, <b>51</b>, and <b>52</b> were selected to evaluate the effectiveness of growing toward the DNA backbone to disrupt the fit of our inhibitors in DNA. 4-Substituted aliphatic alcohol <b>50</b> was negative in the TA97a mutagenicity assay but positive in the UV–vis assay. Of note, the compound could only be tested up to 1000 μg/plate in the bacterial assay, as higher concentration testing was precluded by general cytotoxicity. Pyrazole <b>51</b>, featuring a large substituent at the 5-position of the aminopyridine, which should be pointed directly at the DNA backbone, was negative in both the TA97a mutagenicity assay and UV–vis assays while maintaining Syk potency (Syk IC<sub>50</sub> = 1 nM), representing a potential advance in our efforts. Growing from the 6-position of the aminopyridine, as in triazole <b>52</b>, gave very strong mutagenicity and UV–vis positive results. Though we had gained some favorable data with pyrazole <b>51</b>, its physicochemical properties led to a particularly large cell shift (hWB CysLT IC<sub>50</sub>/Syk IC<sub>50</sub> = 2800× for <b>51</b> versus 98× for <b>42</b>). Overall, the strategy of growing the molecule to mitigate mutagenicity did not seem the best path from an efficiency or physicochemical properties perspective, so we chose to prioritize alternative tactics.</div><div class="NLM_p">Disruption of the π-stacking interaction with DNA was pursued via incorporation of sp<sup>3</sup> groups on the aminopyridine heterocycle (e.g., picolinamide <b>53</b>). Again, this strategy was not successful at overcoming intercalation in our hands, as carboxamide <b>53</b> was positive in both the mutagenicity and UV–vis studies. Having pursued a number of paths with limited success, we decided to look at alternative substructures to mitigate the intercalation liability.</div><div class="NLM_p">Further pursuing a change in the shape of the carboxamide chemotype to grow toward the DNA backbone and disfavor intercalation, we envisioned a carbon-link of the solvent group to the core carboxamide.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> This design was applied to the synthesis of benzimidazole <b>54</b>, which demonstrated proof of concept for generation of a modestly potent/selective carbon-linked Syk inhibitor (Syk IC<sub>50</sub> = 7 nM, 97% of kinases >100×, 101 kinases tested, LRRK2 IC<sub>50</sub> = 130 nM, CHK2 IC<sub>50</sub> = 160 nM, TSSK3 IC<sub>50</sub> = 420 nM) that filled a chemical space different from that of the previous iteration of nitrogen-linked analogs (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> We also pivoted this motif to pyrazinecarboxamide <b>55</b>, which delivered a highly favorable profile (Syk IC<sub>50</sub> = 0.5 nM, 99% of kinases >100×, 101 kinases tested, LRRK2 IC<sub>50</sub> = 30 nM, hWB CysLT IC<sub>50</sub> = 130 nM, rat plasma Cl<sub>p</sub> (Cl<sub>u</sub>) = 44 (255) mL/min/kg, rat <i>T</i><sub>1/2</sub> = 2.8 h). Further, carboxamides <b>54</b> and <b>55</b> were negative in the UV–vis assay for intercalation, and pyrazine <b>55</b> was also negative in the mutagenicity assay in strain TA97a with rat S9. Cyclohexyldiamine <b>55</b> was cytotoxic at concentrations greater than 850 μg/plate, so to mitigate cytotoxicity, the sulfonyldiamine analog <b>56</b> was prepared. Pyrazine <b>56</b> was also negative in the UV–vis assay, as well as the TA97a mutagenicity assay with rat S9, this time tested up to 5000 μg/plate. Delighted by these results, the team set out to further interrogate these findings and compare them in a third assay format. A DNA unwinding assay was utilized to study carboxamides <b>42</b>, <b>55</b>, and <b>56</b>; the results were in full agreement with the TA97a mutagenicity and UV–vis assays, further supporting the viability of the carbon-linked motif as a method for obviating intercalation. Application of the design principles that had been used to overcome ion channel activity and mutagenicity afforded tetrahydropyranyldiamine <b>57</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>). Pyrazine <b>57</b> achieved the desired profile we had targeted from the outset with good intrinsic potency (Syk IC<sub>50</sub> = 0.7 nM), high selectivity (99% of kinases >100×, 101 kinases tested, LRRK2 IC<sub>50</sub> = 33 nM), potent cell functional activity (hWB CysLT IC<sub>50</sub> = 62 nM), and a favorable pharmacokinetic profile in preclinical species (rat plasma Cl<sub>p</sub> (Cl<sub>u</sub>) = 25 (100) mL/min/kg, rat <i>T</i><sub>1/2</sub> = 3.5 h, 29% F). Further, this molecule <b>57</b> posed low risk for ion channel activity and DNA interaction as assessed by our ion channel and UV–vis displacement assays (hERG IC<sub>50</sub> = 22 μM and UV–vis = negative).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p">A recent report from the literature correlated Ames mutagenicity to a metric defined as “ovality” for a series of pyridazinecarboxamide Syk inhibitors.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Ovality was defined as the ratio of the molecular surface area to the minimum surface area.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> We attempted to retrospectively apply a similar calculation to test its predictivity for our studies. We found this metric to be highly sensitive to subtle changes in the geometry of the solvent front heteroaryl substituent. Across our data set, we observed no correlation between ovality and bacterial mutagenicity. As detailed, the key to circumvention of the mutagenicity issue in our case was a mechanistic understanding of the source of the liability (intercalation) along with testable design hypotheses to alter the shape of the carboxamide Syk inhibitors. We pursued both increasing the spherical nature of our molecules as well as two-dimensional perturbation of the spatial fit, ultimately affording the <i>C</i>-linked carboxamides that have shown no mutagenicity risk to date.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Mutagenicity SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0020.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Number represents highest scorable concentration for bacterial mutagenicity negative compounds and lowest concentration a positive score was achieved for positive compounds.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">UV–vis positive defined as <i>K</i><sub>d</sub> ≤ 500 μM.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details and primary data.</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">Ovality calculated using a method adapted from the report by M. C. Lucas et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></div><div></div></div><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlay of <i>N</i>-linked carboxamide (<b>42</b>, red) with <i>C</i>-linked carboxamide (<b>56</b>, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0011.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Profile of pyrazine <b>57</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A novel series of orally efficacious, selective carboxamide Syk inhibitors were discovered via systematic survey of chemotypes prioritized by ligand efficiencies and structural alerts. The critical basic amine functionality of the 3,5-diaminopicolinamides afforded undesired hERG ion channel activity, which was mitigated via modulation of physicochemical properties. PSA emerged as the most effective calculated property in circumventing hERG activity and was used to prospectively design Syk inhibitors devoid of this liability. A mutagenicity risk was subsequently discovered within these chemotypes. The mechanism for mutagenesis was identified as involving intercalation. Several structure-based design hypotheses were interrogated to obviate this issue; modulation of the two-dimensional shape of the molecules led to the identification of an alternative series of <i>C</i>-linked heterocyclic carboxamides, delivering druglike molecules devoid of hERG ion channel activity, mutagenicity, and intercalation risk, while maintaining Syk potency and selectivity.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12"><a href="/doi/suppl/10.1021/jm5018169">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for synthesis of final compounds and intermediates, and descriptions of assays performed. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5018169/suppl_file/jm5018169_si_001.pdf">jm5018169_si_001.pdf (297.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5018169/suppl_file/jm5018169_si_002.csv">jm5018169_si_002.csv (2.07 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm5018169" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44585" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44585" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Michael Ellis</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#96fbfff5fef7f3fac9f3fafaffe5d6fbf3e4f5fdb8f5f9fb"><span class="__cf_email__" data-cfemail="610c08020900040d3e040d0d0812210c0413020a4f020e0c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Altman</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Bass</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John W. Butcher</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan J. Byford</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony Donofrio</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheila Galloway</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew M. Haidle</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Jewell</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nancy Kelly</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erica K. Leccese</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Lee</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Maddess</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Richard Miller</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lily Y. Moy</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ekundayo Osimboni</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan D. Otte</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Vijay Reddy</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kerrie Spencer</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Binyuan Sun</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stella H. Vincent</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gwendolyn J. Ward</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Grace H. C. Woo</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiming Yang</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hani Houshyar</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan B. Northrup</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery Chemistry, ‡Department of Process
Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory
Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d3065e1565-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80862" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80862" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge Jaren Arbanas and Uwe Mueller for routine in vitro pharmacology support, Bruce Adams and Bridget Becker for NMR structural support, and Adam Beard for determination of experimental p<i>K</i><sub>a</sub>’s.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i15" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i15"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i16" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i16"> Abbreviations Used</h2><tr><td class="NLM_term">Syk</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">DMARD</td><td class="NLM_def"><p class="first last">disease-modifying antirheumatic drug</p></td></tr><tr><td class="NLM_term">Fc</td><td class="NLM_def"><p class="first last">fragment, crystallizable</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B cell receptor</p></td></tr><tr><td class="NLM_term">Syk IC<sub>50</sub></td><td class="NLM_def"><p class="first last">recombinant human Syk IC<sub>50</sub></p></td></tr><tr><td class="NLM_term">LBE</td><td class="NLM_def"><p class="first last">ligand binding efficiency</p></td></tr><tr><td class="NLM_term">hWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">MetID</td><td class="NLM_def"><p class="first last">metabolite identification</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Cohen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobburu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maung U, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staten, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=12006504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=935-942&author=M.+H.+Cohenauthor=G.+Williamsauthor=J.+R.+Johnsonauthor=J.+Duanauthor=J.+Gobburuauthor=A.+Rahmanauthor=K.+Bensonauthor=J.+Leightonauthor=S.+K.+Kimauthor=R.+Woodauthor=M.+Rothmannauthor=G.+Chenauthor=K.+Maung+Uauthor=A.+M.+Statenauthor=R.+Pazdur&title=Approval+summary+for+imatinib+mesylate+capsules+in+the+treatment+of+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span></div><div class="casAuthors">Cohen, Martin H.; Williams, Grant; Johnson, John R.; Duan, John; Gobburu, Jogarao; Rahman, Atiqur; Benson, Kimberly; Leighton, John; Kim, Sung K.; Wood, Rebecca; Rothmann, Mark; Chen, Gang; Maung U., Khin; Staten, Ann M.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">935-942</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) results from the breakpoint cluster region-Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis.  Imatinib, an orally administered inhibitor of the breakpoint cluster region-Abl tyrosine kinase, is capable of blocking proliferation and inducing apoptosis in CML cell lines.  In this report, we describe the preclin. profile of imatinib and the data submitted in the New Drug Application that led to its marketing approval.  Chem. manufg. and controls, animal toxicol., and biopharmaceutical data are described.  Results of Phase I and Phase II clin. studies in patients with CML in blast crisis (CML-BC), in accelerated phase (CML-AP), and in chronic phase disease-resistant or intolerant to IFN-α (CML-CP) are summarized.  The basis for marketing approval and postmarketing commitments by the pharmaceutical company are discussed.  Toxicol. studies in the rat, dog, and monkey show the hematol., renal, and hepatobiliary toxicity of imatinib.  Pharmacokinetic studies in patients with CML demonstrate 98% imatinib bioavailability.  The elimination half-lives of the parent drug and the major active metabolite, CGP74588, from plasma are approx. 18 and 40 h, resp.  Approx. 81% of the drug is eliminated in 7 days, 68% in the feces and 13% in the urine.  Cytochrome P 450 3A4 is the main enzyme responsible for imatinib metab.  Phase I and II clin. studies were conducted.  The Phase I study, in 83 CML patients, evaluated oral imatinib doses from 25 to 1000 mg/day.  Dose-limiting toxicity was not obsd.  The three Phase II studies, in CML-CP, CML-AP, and CML-BC, enrolled 1027 patients.  CML-CP patients received 400 mg/day imatinib, whereas CML-AP and CML-BC patients generally received 600 mg/day, imatinib.  Primary study endpoints were cytogenetic response rate (CML-CP) and hematol. response rate (CML-AP and CML-BC).  The cytogenetic response rate for CML-CP patients was 49%.  The hematol. response rate of CML-AP and CML-BC patients was 63 and 26%, resp.  The most common imatinib adverse events were nausea, vomiting, myalgia, edema, and diarrhea.  Elevated liver enzymes and/or bilirubin were reported in 27 patients (2.6%).  On May 10, 2001, imatinib mesylate (Gleevec, formerly known as STI-571 and Glivec), manufd. and distributed by Novartis Pharmaceuticals, East Hanover, NJ, was approved by the United States Food and Drug Administration for the treatment of CML in three clin. settings: CML-BC, CML-AP, and CML-CP.  This report summarizes the Food and Drug Administration's review of the New Drug Application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2majxsiqE3LVg90H21EOLACvtfcHk0li9E4uJoastdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D&md5=8820d9e1126524a6762242f68262ab86</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DBenson%26aufirst%3DK.%26aulast%3DLeighton%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DWood%26aufirst%3DR.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMaung%2BU%26aufirst%3DK.%26aulast%3DStaten%26aufirst%3DA.%2BM.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%2520for%2520imatinib%2520mesylate%2520capsules%2520in%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D935%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bonilla-Hernán, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda-Carús, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Mola, E.</span><span> </span><span class="NLM_article-title">New drugs beyond biologics in rheumatoid arthritis: The kinase inhibitors</span> <span class="citation_source-journal">Rheumatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">–</span> <span class="NLM_lpage">1550</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=1542-1550&author=M.+G.+Bonilla-Hern%C3%A1nauthor=M.+E.+Miranda-Car%C3%BAsauthor=E.+Martin-Mola&title=New+drugs+beyond+biologics+in+rheumatoid+arthritis%3A+The+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonilla-Hern%25C3%25A1n%26aufirst%3DM.%2BG.%26aulast%3DMiranda-Car%25C3%25BAs%26aufirst%3DM.%2BE.%26aulast%3DMartin-Mola%26aufirst%3DE.%26atitle%3DNew%2520drugs%2520beyond%2520biologics%2520in%2520rheumatoid%2520arthritis%253A%2520The%2520kinase%2520inhibitors%26jtitle%3DRheumatology%26date%3D2011%26volume%3D50%26spage%3D1542%26epage%3D1550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Müller-Ladner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pap, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gay, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gay, S.</span><span> </span><span class="NLM_article-title">Mechanisms of disease: The molecular and cellular basis of joint destruction in rheumatoid arthritis</span> <span class="citation_source-journal">J. Clin. Pract. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1038%2Fncprheum0047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=16932639" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=102-110&author=U.+M%C3%BCller-Ladnerauthor=T.+Papauthor=R.+E.+Gayauthor=M.+Neidhartauthor=S.+Gay&title=Mechanisms+of+disease%3A+The+molecular+and+cellular+basis+of+joint+destruction+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fncprheum0047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncprheum0047%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller-Ladner%26aufirst%3DU.%26aulast%3DPap%26aufirst%3DT.%26aulast%3DGay%26aufirst%3DR.%2BE.%26aulast%3DNeidhart%26aufirst%3DM.%26aulast%3DGay%26aufirst%3DS.%26atitle%3DMechanisms%2520of%2520disease%253A%2520The%2520molecular%2520and%2520cellular%2520basis%2520of%2520joint%2520destruction%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Pract.%2520Rheumatol.%26date%3D2005%26volume%3D1%26spage%3D102%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Filer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsonage, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curnow, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainger, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raza, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, C. D.</span><span> </span><span class="NLM_article-title">Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: Site-specific versus activation-dependent survival of T cells and neutrophils</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2096</span><span class="NLM_x">–</span> <span class="NLM_lpage">2108</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1002%2Fart.21930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=16802344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslKhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=2096-2108&author=A.+Filerauthor=G.+Parsonageauthor=E.+Smithauthor=C.+Osborneauthor=A.+M.+Thomasauthor=S.+J.+Curnowauthor=G.+E.+Raingerauthor=K.+Razaauthor=G.+B.+Nashauthor=J.+Lordauthor=M.+Salmonauthor=C.+D.+Buckley&title=Differential+survival+of+leukocyte+subsets+mediated+by+synovial%2C+bone+marrow%2C+and+skin+fibroblasts%3A+Site-specific+versus+activation-dependent+survival+of+T+cells+and+neutrophils"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils</span></div><div class="casAuthors">Filer, Andrew; Parsonage, Greg; Smith, Emily; Osborne, Chloe; Thomas, Andrew M. C.; Curnow, S. John; Rainger, G. Ed; Raza, Karim; Nash, Gerard B.; Lord, Janet; Salmon, Mike; Buckley, Christopher D.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2096-2108</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. Synovial fibroblasts share a no. of phenotype markers with fibroblasts derived from bone marrow.  In this study we investigated the role of matched fibroblasts obtained from 3 different sources (bone marrow, synovium, and skin) to test the hypothesis that synovial fibroblasts share similarities with bone marrow-derived fibroblasts in terms of their ability to support survival of T cells and neutrophils.  Methods. Matched synovial, bone marrow, and skin fibroblasts were established from 8 different patients with rheumatoid arthritis who were undergoing knee or hip surgery.  Resting or activated fibroblasts were cocultured with either CD4 T cells or neutrophils, and the degree of leukocyte survival, apoptosis, and proliferation were measured.  Results. Fibroblasts derived from all 3 sites supported increased survival of CD4 T cells, mediated principally by interferon-β.  However, synovial and bone marrow fibroblasts shared an enhanced site-specific ability to maintain CD4 T cell survival in the absence of proliferation, an effect that was independent of fibroblast activation or proliferation but required direct T cell-fibroblast cell contact.  In contrast, fibroblast-mediated neutrophil survival was less efficient, being independent of the site of origin of the fibroblast but dependent on prior fibroblast activation, and mediated solely by sol. factors, principally granulocyte-macrophage colony-stimulating factor.  Conclusion. These results suggest an important functional role for fibroblasts in the differential accumulation of leukocyte subsets in a variety of tissue microenvironments.  The findings also provide a potential explanation for site-specific differences in the pattern of T cell and neutrophil accumulation obsd. in chronic inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrztSfwzbAyvLVg90H21EOLACvtfcHk0li9E4uJoastdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslKhtbY%253D&md5=8c4565fcd9a1e7fa992f71a3c56ec0a2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fart.21930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.21930%26sid%3Dliteratum%253Aachs%26aulast%3DFiler%26aufirst%3DA.%26aulast%3DParsonage%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DA.%2BM.%26aulast%3DCurnow%26aufirst%3DS.%2BJ.%26aulast%3DRainger%26aufirst%3DG.%2BE.%26aulast%3DRaza%26aufirst%3DK.%26aulast%3DNash%26aufirst%3DG.%2BB.%26aulast%3DLord%26aufirst%3DJ.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DBuckley%26aufirst%3DC.%2BD.%26atitle%3DDifferential%2520survival%2520of%2520leukocyte%2520subsets%2520mediated%2520by%2520synovial%252C%2520bone%2520marrow%252C%2520and%2520skin%2520fibroblasts%253A%2520Site-specific%2520versus%2520activation-dependent%2520survival%2520of%2520T%2520cells%2520and%2520neutrophils%26jtitle%3DArthritis%2520Rheum.%26date%3D2006%26volume%3D54%26spage%3D2096%26epage%3D2108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Nimmerjahn, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravetch, J. V.</span><span> </span><span class="NLM_article-title">Fcγ receptors as regulators of immune responses</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1038%2Fnri2206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=18064051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKrsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=34-47&author=F.+Nimmerjahnauthor=J.+V.+Ravetch&title=Fc%CE%B3+receptors+as+regulators+of+immune+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fcγ receptors as regulators of immune responses</span></div><div class="casAuthors">Nimmerjahn, Falk; Ravetch, Jeffrey V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-47</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In addn. to their role in binding antigen, antibodies can regulate immune responses via interaction with Fc receptors (FcRs).  In recent years, significant progress has been made in understanding the mechanisms that regulate the activity of IgG antibodies in vivo.  Here, the authors discuss recent studies addressing the multifaceted roles of FcRs for IgG (FcγRs) in the immune system and how this knowledge could be translated into novel therapeutic strategies to treat human autoimmune, infectious or malignant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBbBMzHXrMsrVg90H21EOLACvtfcHk0ljZ1vq6gwlK7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKrsLnK&md5=dae5144e17b125fe8665944be2486783</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnri2206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2206%26sid%3Dliteratum%253Aachs%26aulast%3DNimmerjahn%26aufirst%3DF.%26aulast%3DRavetch%26aufirst%3DJ.%2BV.%26atitle%3DFc%25CE%25B3%2520receptors%2520as%2520regulators%2520of%2520immune%2520responses%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D34%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Burmester, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charles-Schoeman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollenhaupt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benda, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C.</span><span> </span><span class="NLM_article-title">Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">451</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=451-460&author=G.+R.+Burmesterauthor=R.+Blancoauthor=C.+Charles-Schoemanauthor=J.+Wollenhauptauthor=C.+Zerbiniauthor=B.+Bendaauthor=D.+Grubenauthor=G.+Wallensteinauthor=S.+Krishnaswamiauthor=S.+H.+Zwillichauthor=T.+Konczauthor=K.+Somaauthor=J.+Bradleyauthor=C.+Mebus&title=Tofacitinib+%28CP-690%2C550%29+in+combination+with+methotrexate+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+tumour+necrosis+factor+inhibitors%3A+A+randomised+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3DBlanco%26aufirst%3DR.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DZerbini%26aufirst%3DC.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DMebus%26aufirst%3DC.%26atitle%3DTofacitinib%2520%2528CP-690%252C550%2529%2520in%2520combination%2520with%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520tumour%2520necrosis%2520factor%2520inhibitors%253A%2520A%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D451%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Geahlen, R. L.</span><span> </span><span class="NLM_article-title">Getting Syk: Spleen tyrosine kinase as a therapeutic target</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=414-422&author=R.+L.+Geahlen&title=Getting+Syk%3A+Spleen+tyrosine+kinase+as+a+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeahlen%26aufirst%3DR.%2BL.%26atitle%3DGetting%2520Syk%253A%2520Spleen%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D414%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Mocsai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tybulewicz, V. L. J.</span><span> </span><span class="NLM_article-title">The Syk tyrosine kinase: A crucial player in diverse biological functions</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1038%2Fnri2765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=20467426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=387-402&author=A.+Mocsaiauthor=J.+Rulandauthor=V.+L.+J.+Tybulewicz&title=The+Syk+tyrosine+kinase%3A+A+crucial+player+in+diverse+biological+functions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The SYK tyrosine kinase: a crucial player in diverse biological functions</span></div><div class="casAuthors">Mocsai, Attila; Ruland, Jurgen; Tybulewicz, Victor L. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-402</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (SYK) is known to have a crucial role in adaptive immune receptor signalling.  However, recent reports indicate that SYK also mediates other, unexpectedly diverse biol. functions, including cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development.  SYK is activated by C-type lectins and integrins, and activates new targets, including the CARD9-BCL-10-MALT1 pathway and the NLRP3 inflammasome.  Studies using Drosophila melanogaster suggest that there is an evolutionarily ancient origin of SYK-mediated signalling.  Moreover, SYK has a crucial role in autoimmune diseases and haematol. malignancies.  This Review summarizes our current understanding of the diverse functions of SYK and how this is being translated for therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3YO5BcMqrf7Vg90H21EOLACvtfcHk0ljZ1vq6gwlK7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D&md5=85857a2b9beb84e0fe74263a90fa8a53</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnri2765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2765%26sid%3Dliteratum%253Aachs%26aulast%3DMocsai%26aufirst%3DA.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%2BJ.%26atitle%3DThe%2520Syk%2520tyrosine%2520kinase%253A%2520A%2520crucial%2520player%2520in%2520diverse%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26spage%3D387%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Pine, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoettler, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banquerigo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossbard, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahn, E.</span><span> </span><span class="NLM_article-title">Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1016%2Fj.clim.2007.03.543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=17537677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1eltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2007&pages=244-257&author=P.+R.+Pineauthor=B.+Changauthor=N.+Schoettlerauthor=M.+L.+Banquerigoauthor=S.+Wangauthor=A.+Lauauthor=F.+Zhaoauthor=E.+B.+Grossbardauthor=D.+G.+Payanauthor=E.+Brahn&title=Inflammation+and+bone+erosion+are+suppressed+in+models+of+rheumatoid+arthritis+following+treatment+with+a+novel+Syk+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor</span></div><div class="casAuthors">Pine, Polly R.; Chang, Betty; Schoettler, Nathan; Banquerigo, Mona L.; Wang, Su; Lau, Angela; Zhao, Feifei; Grossbard, Elliott B.; Payan, Donald G.; Brahn, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-257</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk), a key mediator of immunoreceptor signaling in inflammatory cells, is essential for immune complex-mediated signal transduction initiated by activated receptors for IgG.  In collagen-induced arthritis, R788/R406, a novel and potent small mol. Syk inhibitor suppressed clin. arthritis, bone erosions, pannus formation, and synovitis.  Serum anti-collagen type II antibody levels were unaltered, while the half-life of exogenous antibody was extended when co-administered with R406.  Expression of the targeted kinase (Syk) in synovial tissue correlated with the joint level of inflammatory cell infiltrates and was virtually undetectable in treated rats.  Syk inhibition suppressed synovial cytokines and cartilage oligomeric matrix protein (COMP) in serum, suggesting a sensitive and reliable biomarker for R406 activity.  These results highlight the role of activating Fcgamma receptors in inflammatory synovitis and suggest that interruption of the signaling cascade with a novel Syk inhibitor may be a useful addn. to immunosuppressive disease-modifying anti-rheumatic drugs currently used in the treatment of human autoimmune diseases such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Nm2XObIb37Vg90H21EOLACvtfcHk0lj189DCWbcWcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1eltb0%253D&md5=98b5020fb23cc209e5b7c322024748fb</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2007.03.543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2007.03.543%26sid%3Dliteratum%253Aachs%26aulast%3DPine%26aufirst%3DP.%2BR.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DSchoettler%26aufirst%3DN.%26aulast%3DBanquerigo%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DBrahn%26aufirst%3DE.%26atitle%3DInflammation%2520and%2520bone%2520erosion%2520are%2520suppressed%2520in%2520models%2520of%2520rheumatoid%2520arthritis%2520following%2520treatment%2520with%2520a%2520novel%2520Syk%2520inhibitor%26jtitle%3DClin.%2520Immunol.%26date%3D2007%26volume%3D124%26spage%3D244%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Coffey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ives, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbach, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, U.</span><span> </span><span class="NLM_article-title">Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">350</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1124%2Fjpet.111.188441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=22040680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2012&pages=350-359&author=G.+Coffeyauthor=F.+DeGuzmanauthor=M.+Inagakiauthor=Y.+Pakauthor=S.+M.+Delaneyauthor=D.+Ivesauthor=A.+Betzauthor=Z.+J.+Jiaauthor=A.+Pandeyauthor=D.+Bakerauthor=S.+J.+Hollenbachauthor=D.+R.+Phillipsauthor=U.+Sinha&title=Specific+inhibition+of+spleen+tyrosine+kinase+suppresses+leukocyte+immune+function+and+inflammation+in+animal+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis</span></div><div class="casAuthors">Coffey, Greg; DeGuzman, Francis; Inagaki, Mayuko; Pak, Yvonne; Delaney, Suzanne M.; Ives, Dan; Betz, Andreas; Jia, Zhaozhong J.; Pandey, Anjali; Baker, Dale; Hollenbach, Stanley J.; Phillips, David R.; Sinha, Uma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">350-359</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Based on genetic studies that establish the role of spleen tyrosine kinase (Syk) in immune function, inhibitors of this kinase are being investigated as therapeutic agents for inflammatory diseases.  Because genetic studies eliminate both adapter functions and kinase activity of Syk, it is difficult to delineate the effect of kinase inhibition alone as would be the goal with small-mol. kinase inhibitors.  We tested the hypothesis that specific pharmacol. inhibition of Syk activity retains the immunomodulatory potential of Syk genetic deficiency.  We report here on the discovery of (4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino) pyrimidine-5-carboxamide acetate (P505-15), a highly specific and potent inhibitor of purified Syk (IC50 1-2 nM).  In human whole blood, P505-15 potently inhibited B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, resp.) and Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM).  Similar levels of ex vivo inhibition were measured after dosing in mice (Syk signaling IC50 0.32 μM).  Syk-independent signaling and activation were unaffected at much higher concns., demonstrating the specificity of kinase inhibition in cellular systems.  Oral administration of P505-15 produced dose-dependent anti-inflammatory activity in two rodent models of rheumatoid arthritis.  Statistically significant efficacy was obsd. at concns. that specifically suppressed Syk activity by ∼67%.  Thus specific Syk inhibition can mimic Syk genetic deficiency to modulate immune function, providing a therapeutic strategy in P505-15 for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNR__Bw5qSa7Vg90H21EOLACvtfcHk0lj189DCWbcWcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSltL8%253D&md5=0f79a4c897abe6a25e873d02ee4fee4a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.188441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.188441%26sid%3Dliteratum%253Aachs%26aulast%3DCoffey%26aufirst%3DG.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DDelaney%26aufirst%3DS.%2BM.%26aulast%3DIves%26aufirst%3DD.%26aulast%3DBetz%26aufirst%3DA.%26aulast%3DJia%26aufirst%3DZ.%2BJ.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DHollenbach%26aufirst%3DS.%2BJ.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DSinha%26aufirst%3DU.%26atitle%3DSpecific%2520inhibition%2520of%2520spleen%2520tyrosine%2520kinase%2520suppresses%2520leukocyte%2520immune%2520function%2520and%2520inflammation%2520in%2520animal%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D340%26spage%3D350%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pashine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S.-L.</span><span> </span><span class="NLM_article-title">Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: Implications for SYK inhibitors in autoimmune disease therapy</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">R146</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=R146&author=C.+Liaoauthor=J.+Hsuauthor=Y.+Kimauthor=D.-Q.+Huauthor=D.+Xuauthor=J.+Zhangauthor=A.+Pashineauthor=J.+Menkeauthor=T.+Whittardauthor=N.+Romeroauthor=T.+Truittauthor=M.+Sladeauthor=C.+Lukacsauthor=J.+Hermannauthor=M.+Zhouauthor=M.+Lucasauthor=S.+Narulaauthor=J.+DeMartinoauthor=S.-L.+Tan&title=Selective+inhibition+of+spleen+tyrosine+kinase+%28SYK%29+with+a+novel+orally+bioavailable+small+molecule+inhibitor%2C+RO9021%2C+impinges+on+various+innate+and+adaptive+immune+responses%3A+Implications+for+SYK+inhibitors+in+autoimmune+disease+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DMenke%26aufirst%3DJ.%26aulast%3DWhittard%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DN.%26aulast%3DTruitt%26aufirst%3DT.%26aulast%3DSlade%26aufirst%3DM.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DHermann%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DM.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DS.-L.%26atitle%3DSelective%2520inhibition%2520of%2520spleen%2520tyrosine%2520kinase%2520%2528SYK%2529%2520with%2520a%2520novel%2520orally%2520bioavailable%2520small%2520molecule%2520inhibitor%252C%2520RO9021%252C%2520impinges%2520on%2520various%2520innate%2520and%2520adaptive%2520immune%2520responses%253A%2520Implications%2520for%2520SYK%2520inhibitors%2520in%2520autoimmune%2520disease%2520therapy%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2013%26volume%3D15%26spage%3DR146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Currie, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansdon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span> </span><span class="NLM_article-title">Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3856</span><span class="NLM_x">–</span> <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm500228a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3856-3873&author=K.+S.+Currieauthor=J.+E.+Kropfauthor=T.+Leeauthor=P.+Blomgrenauthor=J.+Xuauthor=Z.+Zhaoauthor=S.+Gallionauthor=J.+A.+Whitneyauthor=D.+Maclinauthor=E.+B.+Lansdonauthor=P.+Maciejewskiauthor=A.+M.+Rossiauthor=H.+Rongauthor=J.+Macalusoauthor=J.+Barbosaauthor=J.+A.+Di+Paoloauthor=S.+A.+Mitchell&title=Discovery+of+GS-9973%2C+a+selective+and+orally+efficacious+inhibitor+of+spleen+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm500228a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500228a%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DMaclin%26aufirst%3DD.%26aulast%3DLansdon%26aufirst%3DE.%2BB.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26atitle%3DDiscovery%2520of%2520GS-9973%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520spleen%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3856%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Weinblatt, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavanaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musser, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossbard, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magilavy, D. B.</span><span> </span><span class="NLM_article-title">Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">378</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.3899%2Fjrheum.120923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=23378467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12qs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=369-378&author=M.+E.+Weinblattauthor=A.+Kavanaughauthor=M.+C.+Genoveseauthor=D.+A.+Jonesauthor=T.+K.+Musserauthor=E.+B.+Grossbardauthor=D.+B.+Magilavy&title=Effects+of+fostamatinib+%28R788%29%2C+an+oral+spleen+tyrosine+kinase+inhibitor%2C+on+health-related+quality+of+life+in+patients+with+active+rheumatoid+arthritis%3A+analyses+of+patient-reported+outcomes+from+a+randomized%2C+double-blind%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Weinblatt, Michael E.; Kavanaugh, Arthur; Genovese, Mark C.; Jones, David A.; Musser, Theresa K.; Grossbard, Elliott B.; Magilavy, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-378</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective. To assess the influence of fostamatinib on patient-reported outcomes (PRO) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX).  Methods. Patients taking background MTX (N = 457) were enrolled in a phase II clin. trial (NCT00665925) and randomized equally to placebo, fostamatinib 100 mg twice daily (bid), or fostamatinib 150 mg once daily (qd) for 24 wk.  Self-administered PRO measures included pain, patient's global assessment (PtGA) of disease activity, phys. function, health-related quality of life (HRQOL), and fatigue.  Mean change from baseline and a responder anal. of the proportion of patients achieving a minimal clin. important difference were detd.  Results. At Week 24, there were statistically significant improvements in pain, PtGA, phys. function, fatigue, and the phys. component summary of the Medical Outcomes Study Short Form-36 (SF-36) for fostamatinib 100 mg bid compared with placebo.  Mean (std. error) changes from baseline in the fostamatinib 100 mg bid group vs. the placebo group were -31.3 (2.45) vs. -17.8 (2.45), p < 0.001 for pain; -29.1 (2.26) vs. -16.7 (2.42), p < 0.001 for PtGA; -0.647 (0.064) vs. -0.343 (0.062), p < 0.001 for phys. function; 7.40 (1.00) vs. 4.50 (0.94), p < 0.05 for fatigue; 8.52 (0.77) vs. 4.90 (0.78), p < 0.01 for SF-36 phys. component score; and 3.99 (0.93) vs. 3.71 (0.99), p = 0.83 for SF-36 mental component score.  Patients receiving fostamatinib 150 mg qd showed improvements in some PRO, including phys. function.  Conclusion. Patients treated with fostamatinib 100 mg bid showed significant improvements in HRQOL outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIPy0NRTaLcLVg90H21EOLACvtfcHk0ljy9OE3kGlJsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12qs7s%253D&md5=830c76d39d46e7ffa679a5530d80bc50</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.120923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.120923%26sid%3Dliteratum%253Aachs%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DJones%26aufirst%3DD.%2BA.%26aulast%3DMusser%26aufirst%3DT.%2BK.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DMagilavy%26aufirst%3DD.%2BB.%26atitle%3DEffects%2520of%2520fostamatinib%2520%2528R788%2529%252C%2520an%2520oral%2520spleen%2520tyrosine%2520kinase%2520inhibitor%252C%2520on%2520health-related%2520quality%2520of%2520life%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520analyses%2520of%2520patient-reported%2520outcomes%2520from%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Rheumatol.%26date%3D2013%26volume%3D40%26spage%3D369%26epage%3D378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Edwards, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczepanski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szechinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipowicz-Sosnowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Close, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, T.</span><span> </span><span class="NLM_article-title">Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2572</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1056%2FNEJMoa032534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=15201414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFKntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2572-81&author=J.+Edwardsauthor=L.+Szczepanskiauthor=J.+Szechinskiauthor=A.+Filipowicz-Sosnowskaauthor=P.+Emeryauthor=D.+Closeauthor=R.+Stevensauthor=T.+Shaw&title=Efficacy+of+B-cell-targeted+therapy+with+rituximab+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis</span></div><div class="casAuthors">Edwards, Jonathan C. W.; Szczepanski, Leszek; Szechinski, Jacek; Filipowicz-Sosnowska, Anna; Emery, Paul; Close, David R.; Stevens, Randall M.; Shaw, Tim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2572-2581</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clin. improvements for patients with rheumatoid arthritis.  To confirm these observations, we conducted a randomized, double-blind, controlled study.  We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (≥10 mgper week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate.  Responses defined according to the criteria of the American College of Rheumatol. (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses).  At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent).  In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P≤0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P≤0.004).  All ACRresponses were maintained at week 48 in the rituximab-methotrexate group.  The majority of adverse events occurred with the first rituximab infusion: at 24 wk, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups.  Peripheral-blood Ig concns. remained within normal ranges.  In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1mDg3P-3cC7Vg90H21EOLACvtfcHk0ljxcMt3wpXq-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFKntrc%253D&md5=3b8abe2027557b0733fc5d81d28965f7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032534%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DJ.%26aulast%3DSzczepanski%26aufirst%3DL.%26aulast%3DSzechinski%26aufirst%3DJ.%26aulast%3DFilipowicz-Sosnowska%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DP.%26aulast%3DClose%26aufirst%3DD.%26aulast%3DStevens%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DT.%26atitle%3DEfficacy%2520of%2520B-cell-targeted%2520therapy%2520with%2520rituximab%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2572%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><div class="note"><p class="first last">For the role of VEGF inhibition in hypertension see:</p></div><span class="NLM_contrib-group">Pande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangethal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javle, M.</span><span> </span><span class="NLM_article-title">Hypertension secondary to anti-angiogenic therapy: Experience with bevacizumab</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3465</span><span class="NLM_x">–</span> <span class="NLM_lpage">3470</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=17972502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWjs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=3465-3470&author=A.+Pandeauthor=J.+Lombardoauthor=E.+Spangethalauthor=M.+Javle&title=Hypertension+secondary+to+anti-angiogenic+therapy%3A+Experience+with+bevacizumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab</span></div><div class="casAuthors">Pande, Amitkumar; Lombardo, Jeffrey; Spangenthal, Edward; Javle, Milind</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5B</span>),
    <span class="NLM_cas:pages">3465-3470</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Hypertension (HT) is a common complication of anti-angiogenic therapy.  Its incidence, treatment and complications are undefined.  Patients and Methods: Retrospective review of patients treated with bevacizumab (BV) from 2003-5.  Common toxicity criteria (CTC) for adverse events version 3.0 were used.  Results: Fifty-five out of the 154 patients treated with BV (35%) experienced HT.  Eleven (20%) developed a new onset HT and 44 (80%) experienced an exacerbation of pre-existing HT.  HT developed after a median of 11 wk at a median BV dose of 10 mg/kg.  HT severity was grade 1 (n = 1), grade 2 (n = 29) or grade 3 (n = 22); 3 experienced hypertensive complications.  HT was controlled in 47 (85%); BV was discontinued in 3.  The angiotensin-converting enzyme inhibitor (ACE-I), quinapril was commonly used and resulted in better HT control than ACE-II, calcium channel or beta antagonists.  Conclusion: HT assocd. with bevacizumab therapy is a manageable toxicity with the use of ACE-I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqvYpPYDdty7Vg90H21EOLACvtfcHk0ljxcMt3wpXq-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWjs7zK&md5=9ed49f6d9626ebc0ee3d39de5740b22c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPande%26aufirst%3DA.%26aulast%3DLombardo%26aufirst%3DJ.%26aulast%3DSpangethal%26aufirst%3DE.%26aulast%3DJavle%26aufirst%3DM.%26atitle%3DHypertension%2520secondary%2520to%2520anti-angiogenic%2520therapy%253A%2520Experience%2520with%2520bevacizumab%26jtitle%3DAnticancer%2520Res.%26date%3D2007%26volume%3D27%26spage%3D3465%26epage%3D3470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Suljagic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennardo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efremov, D. G.</span><span> </span><span class="NLM_article-title">The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">4894</span><span class="NLM_x">–</span> <span class="NLM_lpage">4905</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4894-4905&author=M.+Suljagicauthor=P.+G.+Longoauthor=S.+Bennardoauthor=E.+Perlasauthor=G.+Leoneauthor=L.+Laurentiauthor=D.+G.+Efremov&title=The+Syk+inhibitor+fostamatinib+disodium+%28R788%29+inhibits+tumor+growth+in+the+E%CE%BC-TCL1+transgenic+mouse+model+of+CLL+by+blocking+antigen-dependent+B-cell+receptor+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuljagic%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DP.%2BG.%26aulast%3DBennardo%26aufirst%3DS.%26aulast%3DPerlas%26aufirst%3DE.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DLaurenti%26aufirst%3DL.%26aulast%3DEfremov%26aufirst%3DD.%2BG.%26atitle%3DThe%2520Syk%2520inhibitor%2520fostamatinib%2520disodium%2520%2528R788%2529%2520inhibits%2520tumor%2520growth%2520in%2520the%2520E%25CE%25BC-TCL1%2520transgenic%2520mouse%2520model%2520of%2520CLL%2520by%2520blocking%2520antigen-dependent%2520B-cell%2520receptor%2520signaling%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D4894%26epage%3D4905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Friedberg, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweetenham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vose, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacasce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer-Cutillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cripe, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterba, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipp, M. A.</span><span> </span><span class="NLM_article-title">Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2578</span><span class="NLM_x">–</span> <span class="NLM_lpage">2585</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=2578-2585&author=J.+W.+Friedbergauthor=J.+Sharmanauthor=J.+Sweetenhamauthor=P.+B.+Johnstonauthor=J.+M.+Voseauthor=A.+Lacasceauthor=J.+Schaefer-Cutilloauthor=S.+De+Vosauthor=R.+Sinhaauthor=J.+P.+Leonardauthor=L.+D.+Cripeauthor=S.+A.+Gregoryauthor=M.+P.+Sterbaauthor=A.+M.+Loweauthor=R.+Levyauthor=M.+A.+Shipp&title=Inhibition+of+Syk+with+fostamatinib+disodium+has+significant+clinical+activity+in+non-Hodgkin+lymphoma+and+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFriedberg%26aufirst%3DJ.%2BW.%26aulast%3DSharman%26aufirst%3DJ.%26aulast%3DSweetenham%26aufirst%3DJ.%26aulast%3DJohnston%26aufirst%3DP.%2BB.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DLacasce%26aufirst%3DA.%26aulast%3DSchaefer-Cutillo%26aufirst%3DJ.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DLeonard%26aufirst%3DJ.%2BP.%26aulast%3DCripe%26aufirst%3DL.%2BD.%26aulast%3DGregory%26aufirst%3DS.%2BA.%26aulast%3DSterba%26aufirst%3DM.%2BP.%26aulast%3DLowe%26aufirst%3DA.%2BM.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DShipp%26aufirst%3DM.%2BA.%26atitle%3DInhibition%2520of%2520Syk%2520with%2520fostamatinib%2520disodium%2520has%2520significant%2520clinical%2520activity%2520in%2520non-Hodgkin%2520lymphoma%2520and%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D2578%26epage%3D2585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ulanova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puttagunta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Befus, A. D.</span><span> </span><span class="NLM_article-title">Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">901</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1517%2F14728222.9.5.901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=16185147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVartbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=901-921&author=M.+Ulanovaauthor=F.+Dutaauthor=L.+Puttaguntaauthor=A.+D.+Schreiberauthor=A.+D.+Befus&title=Spleen+tyrosine+kinase+%28Syk%29+as+a+novel+target+for+allergic+asthma+and+rhinitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis</span></div><div class="casAuthors">Ulanova, Marina; Duta, Florentina; Puttagunta, Lakshmi; Schreiber, Alan D.; Befus, A. Dean</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">901-921</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Allergic asthma and rhinitis are prevalent diseases in the modern world, both marked by inflammation of the airways.  The spleen tyrosine kinase (Syk) plays a crit. role in the regulation of such immune and inflammatory responses.  Although Syk is best known as a key component of immunoreceptor signaling complexes in leukocytes, recent studies demonstrated Syk expression in cells outside the haematopoietic lineage.  Moreover, in recent years, it has been established that Syk is involved in various signaling cascades including those originating from integrin and cytokine receptors.  Thus, Syk likely has a much wider biol. role than previously recognized.  Specific inhibition of Syk using aerosolised antisense oligonucleotides in liposome complexes significantly decreased lung inflammatory responses in exptl. asthma and acute lung injury models.  In addn., pharmacol. inhibitors of Syk have been recently developed with potential for use as therapeutics.  However, in the development and the rational delivery of drugs targeting Syk, it is important to consider the multiple cell types that express this kinase and the potential effects of its inhibition on various physiol. functions.  This review focuses on the recent data and the emerging ideas about Syk as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5sKbhtE4OO7Vg90H21EOLACvtfcHk0lh8iP125fUSfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVartbbJ&md5=8cb1ce3346dabd9ffa4a8d380746f5b5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F14728222.9.5.901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.9.5.901%26sid%3Dliteratum%253Aachs%26aulast%3DUlanova%26aufirst%3DM.%26aulast%3DDuta%26aufirst%3DF.%26aulast%3DPuttagunta%26aufirst%3DL.%26aulast%3DSchreiber%26aufirst%3DA.%2BD.%26aulast%3DBefus%26aufirst%3DA.%2BD.%26atitle%3DSpleen%2520tyrosine%2520kinase%2520%2528Syk%2529%2520as%2520a%2520novel%2520target%2520for%2520allergic%2520asthma%2520and%2520rhinitis%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2005%26volume%3D9%26spage%3D901%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Moy, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caniga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieber, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirkowski, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northrup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houshyar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackower, M. A.</span><span> </span><span class="NLM_article-title">Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1165%2Frcmb.2013-0200OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=23889698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyhu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=1085-1092&author=L.+Y.+Moyauthor=Y.+Jiaauthor=M.+Canigaauthor=G.+Lieberauthor=M.+Gilauthor=X.+Fernandezauthor=E.+Sirkowskiauthor=R.+Millerauthor=J.+P.+Alexanderauthor=H.-H.+Leeauthor=J.+D.+Shinauthor=J.+M.+Ellisauthor=H.+Chenauthor=A.+Wilhelmauthor=H.+Yuauthor=S.+Vincentauthor=R.+W.+Chapmanauthor=N.+Kellyauthor=E.+Hickeyauthor=W.+M.+Abrahamauthor=A.+Northrupauthor=T.+Millerauthor=H.+Houshyarauthor=M.+A.+Crackower&title=Inhibition+of+spleen+tyrosine+kinase+attenuates+allergen-mediated+airway+constriction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction</span></div><div class="casAuthors">Moy, Lily Y.; Jia, Yanlin; Caniga, Michael; Lieber, Gissela; Gil, Malgorzata; Fernandez, Xiomara; Sirkowski, Erich; Miller, Richard; Alexander, Jessica P.; Lee, Hyun-Hee; Shin, John D.; Ellis, J. Michael; Chen, Hongmin; Wilhelm, Alan; Yu, Hongshi; Vincent, Stella; Chapman, Richard W.; Kelly, Nancy; Hickey, Emily; Abraham, William M.; Northrup, Alan; Miller, Thomas; Houshyar, Hani; Crackower, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (SYK) is a key activator of signaling pathways downstream of multiple surface receptors implicated in asthma.  SYK function has been extensively studied in mast cells downstream of the high-affinity IgE receptor, FcεR1.  Preclin. studies have demonstrated a role for SYK in models of allergic inflammation, but a role in airway constriction has not been demonstrated.  Here, we have used a potent and selective pharmacol. inhibitor of SYK to det. the role of SYK in allergen-mediated inflammation and airway constriction in preclin. models.  Attenuation of allergic airway responses was evaluated in a rat passive anaphylaxis model and rat and sheep inhaled allergen challenge models, as well as an ex vivo model of allergen-mediated airway constriction in rats and cynomolgus monkeys.  Pharmacol. inhibition of SYK dose-dependently blocked IgE-mediated tracheal plasma extravasation in rats.  In a rat ovalbumin-sensitized airway challenge model, oral dosing with an SYK inhibitor led to a dose-dependent redn. in lung inflammatory cells.  Ex vivo anal. of allergen-induced airway constriction in ovalbumin-sensitized brown Norway rats showed a complete attenuation with treatment of a SYK inhibitor, as well as a complete block of allergen-induced serotonin release.  Similarly, allergen-mediated airway constriction was attenuated in ex vivo studies from nonhuman primate lungs.  I.v. administration of an SYK inhibitor attenuated both early- and late-phase allergen-induced increases in airway resistance in an Ascaris-sensitive sheep allergen challenge model.  These data support a key role for SYK signaling in mediating allergic airway responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh2FAd7eonHLVg90H21EOLACvtfcHk0lh8iP125fUSfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyhu7fF&md5=8091e1196bdce7352838f5ef9d699f42</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2013-0200OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2013-0200OC%26sid%3Dliteratum%253Aachs%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DCaniga%26aufirst%3DM.%26aulast%3DLieber%26aufirst%3DG.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DX.%26aulast%3DSirkowski%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DAlexander%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DShin%26aufirst%3DJ.%2BD.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWilhelm%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DS.%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DKelly%26aufirst%3DN.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DAbraham%26aufirst%3DW.%2BM.%26aulast%3DNorthrup%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DHoushyar%26aufirst%3DH.%26aulast%3DCrackower%26aufirst%3DM.%2BA.%26atitle%3DInhibition%2520of%2520spleen%2520tyrosine%2520kinase%2520attenuates%2520allergen-mediated%2520airway%2520constriction%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2013%26volume%3D49%26spage%3D1085%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Surry, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Dialkylbiaryl phosphines in Pd-catalyzed amination: A user’s guide</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1039%2Fc0sc00331j" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=27-50&author=D.+S.+Surryauthor=S.+L.+Buchwald&title=Dialkylbiaryl+phosphines+in+Pd-catalyzed+amination%3A+A+user%E2%80%99s+guide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dialkylbiaryl phosphines in Pd-catalyzed amination: a user's guide</span></div><div class="casAuthors">Surry, David S.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-50</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Dialkylbiaryl phosphines are a valuable class of ligand for Pd-catalyzed amination reactions and have been applied in a range of contexts.  This perspective attempts to aid the reader in the selection of the best choice of reaction conditions and ligand of this class for the most commonly encountered and practically important substrate combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0vbHHdx-_rVg90H21EOLACvtfcHk0lh8iP125fUSfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbnM&md5=8743358f11af138189d106c51b5942b9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc0sc00331j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0sc00331j%26sid%3Dliteratum%253Aachs%26aulast%3DSurry%26aufirst%3DD.%2BS.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DDialkylbiaryl%2520phosphines%2520in%2520Pd-catalyzed%2520amination%253A%2520A%2520user%25E2%2580%2599s%2520guide%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26spage%3D27%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Miyaura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3437</span><span class="NLM_x">–</span> <span class="NLM_lpage">3440</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1979&pages=3437-3440&author=N.+Miyauraauthor=K.+Yamadaauthor=A.+Suzuki&title=A+new+stereospecific+cross-coupling+by+the+palladium-catalyzed+reaction+of+1-alkenylboranes+with+1-alkenyl+or+1-alkynyl+halides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DA%2520new%2520stereospecific%2520cross-coupling%2520by%2520the%2520palladium-catalyzed%2520reaction%2520of%25201-alkenylboranes%2520with%25201-alkenyl%2520or%25201-alkynyl%2520halides%26jtitle%3DTetrahedron%2520Lett.%26date%3D1979%26volume%3D36%26spage%3D3437%26epage%3D3440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Hisamichi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoshima, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span> </span><span class="NLM_article-title">Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4936</span><span class="NLM_x">–</span> <span class="NLM_lpage">4951</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=4936-4951&author=H.+Hisamichiauthor=R.+Naitoauthor=A.+Toyoshimaauthor=N.+Kawanoauthor=A.+Ichikawaauthor=A.+Oritaauthor=M.+Oritaauthor=N.+Hamadaauthor=M.+Takeuchiauthor=M.+Ohtaauthor=S.+Tsukamoto&title=Synthetic+studies+on+novel+Syk+inhibitors.+Part+1%3A+Synthesis+and+structure-activity+relationships+of+pyrimidine-5-carboxamide+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHisamichi%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DR.%26aulast%3DToyoshima%26aufirst%3DA.%26aulast%3DKawano%26aufirst%3DN.%26aulast%3DIchikawa%26aufirst%3DA.%26aulast%3DOrita%26aufirst%3DA.%26aulast%3DOrita%26aufirst%3DM.%26aulast%3DHamada%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%26atitle%3DSynthetic%2520studies%2520on%2520novel%2520Syk%2520inhibitors.%2520Part%25201%253A%2520Synthesis%2520and%2520structure-activity%2520relationships%2520of%2520pyrimidine-5-carboxamide%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D4936%26epage%3D4951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span> </span><span class="NLM_article-title">Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=466-470&author=A.+G.+Villasenorauthor=R.+Kendraauthor=H.+Hoauthor=S.+Wangauthor=E.+Pappauthor=D.+Shawauthor=J.+W.+Barnettauthor=M.+F.+Brownerauthor=A.+Kuglstatter&title=Structural+insights+for+design+of+potent+spleen+tyrosine+kinase+inhibitors+from+crystallographic+analysis+of+three+inhibitor+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DKendra%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPapp%26aufirst%3DE.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26aulast%3DKuglstatter%26aufirst%3DA.%26atitle%3DStructural%2520insights%2520for%2520design%2520of%2520potent%2520spleen%2520tyrosine%2520kinase%2520inhibitors%2520from%2520crystallographic%2520analysis%2520of%2520three%2520inhibitor%2520complexes%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D73%26spage%3D466%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleo, M. D.</span><span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+A+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0liGJkBSZM_Oiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520A%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><div class="note"><p class="first last">Data for pyridazinecarboxamide <b>21</b> from</p></div><span class="NLM_contrib-group">Lucas, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagirath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiao, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy-Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padilla, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polonchuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Railkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadava, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span> </span><span class="NLM_article-title">Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2683</span><span class="NLM_x">–</span> <span class="NLM_lpage">2691</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401982j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2683-2691&author=M.+C.+Lucasauthor=N.+Bhagirathauthor=E.+Chiaoauthor=D.+M.+Goldsteinauthor=J.+C.+Hermannauthor=P.-Y.+Hsuauthor=S.+Kirchnerauthor=J.+J.+Kennedy-Smithauthor=A.+Kuglstatterauthor=C.+Lukacsauthor=J.+Menkeauthor=L.+Niuauthor=F.+Padillaauthor=Y.+Pengauthor=L.+Polonchukauthor=A.+Railkarauthor=M.+Sladeauthor=M.+Sothauthor=D.+Xuauthor=P.+Yadavaauthor=C.+Yeeauthor=M.+Zhouauthor=C.+Liao&title=Using+ovality+to+predict+nonmutagenic%2C+orally+efficacious+pyridazine+amides+as+cell+specific+spleen+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm401982j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401982j%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DBhagirath%26aufirst%3DN.%26aulast%3DChiao%26aufirst%3DE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHermann%26aufirst%3DJ.%2BC.%26aulast%3DHsu%26aufirst%3DP.-Y.%26aulast%3DKirchner%26aufirst%3DS.%26aulast%3DKennedy-Smith%26aufirst%3DJ.%2BJ.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DMenke%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DPadilla%26aufirst%3DF.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DPolonchuk%26aufirst%3DL.%26aulast%3DRailkar%26aufirst%3DA.%26aulast%3DSlade%26aufirst%3DM.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DYadava%26aufirst%3DP.%26aulast%3DYee%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DC.%26atitle%3DUsing%2520ovality%2520to%2520predict%2520nonmutagenic%252C%2520orally%2520efficacious%2520pyridazine%2520amides%2520as%2520cell%2520specific%2520spleen%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2683%26epage%3D2691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">This level of Zap70 versus Syk enzymatic selectivity was generally maintained for all carboxamides.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span> </span><span class="NLM_article-title">Drug-like properties and the causes of poor solubility and poor permeability</span> <span class="citation_source-journal">J. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1016%2FS1056-8719%2800%2900107-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=11274893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A280%3ADC%252BD3M7os1OjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=235-249&author=C.+A.+Lipinski&title=Drug-like+properties+and+the+causes+of+poor+solubility+and+poor+permeability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-like properties and the causes of poor solubility and poor permeability</span></div><div class="casAuthors">Lipinski C A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacological and toxicological methods</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-49</span>
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    </div><div class="casAbstract">There are currently about 10000 drug-like compounds.  These are sparsely, rather than uniformly, distributed through chemistry space.  True diversity does not exist in experimental combinatorial chemistry screening libraries.  Absorption, distribution, metabolism, and excretion (ADME) and chemical reactivity-related toxicity is low, while biological receptor activity is higher dimensional in chemistry space, and this is partly explainable by evolutionary pressures on ADME to deal with endobiotics and exobiotics.  ADME is hard to predict for large data sets because current ADME experimental screens are multi-mechanisms, and predictions get worse as more data accumulates.  Currently, screening for biological receptor activity precedes or is concurrent with screening for properties related to "drugability." In the future, "drugability" screening may precede biological receptor activity screening.  The level of permeability or solubility needed for oral absorption is related to potency.  The relative importance of poor solubility and poor permeability towards the problem of poor oral absorption depends on the research approach used for lead generation.  A "rational drug design" approach as exemplified by Merck advanced clinical candidates leads to time-dependent higher molecular weight, higher H-bonding properties, unchanged lipophilicity, and, hence, poorer permeability.  A high throughput screening (HTS)-based approach as exemplified by unpublished data on Pfizer (Groton, CT) early candidates leads to higher molecular weight, unchanged H-bonding properties, higher lipophilicity, and, hence, poorer aqueous solubility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmUcEou3dTa_EeosoOnpOLfW6udTcc2eY89NXSO8uD4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7os1OjsQ%253D%253D&md5=aeb705afe1eccaceaf441c7a19f13ecc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2800%2900107-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252800%252900107-6%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DDrug-like%2520properties%2520and%2520the%2520causes%2520of%2520poor%2520solubility%2520and%2520poor%2520permeability%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%26date%3D2000%26volume%3D44%26spage%3D235%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lgzH0D-4Psn2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Penna, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karczewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span> </span><span class="NLM_article-title">Functional and pharmacological properties of canine ERG potassium channels</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=256-267&author=J.+Wangauthor=K.+Della+Pennaauthor=H.+Wangauthor=J.+Karczewskiauthor=T.+M.+Connollyauthor=K.+S.+Koblanauthor=P.+B.+Bennettauthor=J.+J.+Salata&title=Functional+and+pharmacological+properties+of+canine+ERG+potassium+channels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDella%2BPenna%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKarczewski%26aufirst%3DJ.%26aulast%3DConnolly%26aufirst%3DT.%2BM.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DBennett%26aufirst%3DP.%2BB.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26atitle%3DFunctional%2520and%2520pharmacological%2520properties%2520of%2520canine%2520ERG%2520potassium%2520channels%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D2003%26volume%3D284%26spage%3D256%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><div class="note"><p class="first last">Higher throughput binding assay measures displacement of MK-499, a strong binder to the hERG ion channel.</p></div><span class="NLM_contrib-group">Priest, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. L.</span><span> </span><span class="NLM_article-title">Role of hERG potassium channel assays in drug development</span> <span class="citation_source-journal">Channels</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=87-93&author=B.+T.+Priestauthor=I.+M.+Bellauthor=M.+L.+Garcia&title=Role+of+hERG+potassium+channel+assays+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26atitle%3DRole%2520of%2520hERG%2520potassium%2520channel%2520assays%2520in%2520drug%2520development%26jtitle%3DChannels%26date%3D2008%26volume%3D2%26spage%3D87%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Kawai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span> </span><span class="NLM_article-title">A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1110</span><span class="NLM_x">–</span> <span class="NLM_lpage">1116</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2011&pages=1110-1116&author=Y.+Kawaiauthor=S.+Tsukamotoauthor=J.+Itoauthor=K.+Akimotoauthor=M.+Takahashi&title=A+risk+assessment+of+human+ether-a-go-go-related+gene+potassium+channel+inhibition+by+using+lipophilicity+and+basicity+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DY.%26aulast%3DTsukamoto%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DJ.%26aulast%3DAkimoto%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DM.%26atitle%3DA%2520risk%2520assessment%2520of%2520human%2520ether-a-go-go-related%2520gene%2520potassium%2520channel%2520inhibition%2520by%2520using%2520lipophilicity%2520and%2520basicity%2520for%2520drug%2520discovery%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2011%26volume%3D59%26spage%3D1110%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Liddle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douault, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elwes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayhow, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavens, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, A. G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez-Molina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skone, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smithers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weingarten, G. G.</span><span> </span><span class="NLM_article-title">Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6188</span><span class="NLM_x">–</span> <span class="NLM_lpage">6194</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6188-6194&author=J.+Liddleauthor=F.+L.+Atkinsonauthor=M.+D.+Barkerauthor=P.+S.+Carterauthor=N.+R.+Curtisauthor=R.+P.+Davisauthor=C.+Douaultauthor=M.+C.+Dicksonauthor=D.+Elwesauthor=N.+S.+Gartonauthor=M.+Grayauthor=T.+G.+Hayhowauthor=C.+I.+Hobbsauthor=E.+Jonesauthor=S.+Leachauthor=K.+Leavensauthor=H.+D.+Lewisauthor=S.+McClearyauthor=M.+Neuauthor=V.+K.+Patelauthor=A.+G.+S.+Prestonauthor=C.+Ramirez-Molinaauthor=T.+J.+Shipleyauthor=P.+A.+Skoneauthor=N.+Smithersauthor=D.+O.+Somersauthor=A.+L.+Walkerauthor=R.+J.+Watsonauthor=G.+G.+Weingarten&title=Discovery+of+GSK143%2C+a+highly+potent%2C+selective+and+orally+efficacious+spleen+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiddle%26aufirst%3DJ.%26aulast%3DAtkinson%26aufirst%3DF.%2BL.%26aulast%3DBarker%26aufirst%3DM.%2BD.%26aulast%3DCarter%26aufirst%3DP.%2BS.%26aulast%3DCurtis%26aufirst%3DN.%2BR.%26aulast%3DDavis%26aufirst%3DR.%2BP.%26aulast%3DDouault%26aufirst%3DC.%26aulast%3DDickson%26aufirst%3DM.%2BC.%26aulast%3DElwes%26aufirst%3DD.%26aulast%3DGarton%26aufirst%3DN.%2BS.%26aulast%3DGray%26aufirst%3DM.%26aulast%3DHayhow%26aufirst%3DT.%2BG.%26aulast%3DHobbs%26aufirst%3DC.%2BI.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DS.%26aulast%3DLeavens%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DH.%2BD.%26aulast%3DMcCleary%26aufirst%3DS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DV.%2BK.%26aulast%3DPreston%26aufirst%3DA.%2BG.%2BS.%26aulast%3DRamirez-Molina%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DT.%2BJ.%26aulast%3DSkone%26aufirst%3DP.%2BA.%26aulast%3DSmithers%26aufirst%3DN.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DWeingarten%26aufirst%3DG.%2BG.%26atitle%3DDiscovery%2520of%2520GSK143%252C%2520a%2520highly%2520potent%252C%2520selective%2520and%2520orally%2520efficacious%2520spleen%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6188%26epage%3D6194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><a href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf" class="extLink">http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.ich.org%2Ffileadmin%2FPublic_Web_Site%2FICH_Products%2FGuidelines%2FSafety%2FS2_R1%2FStep4%2FS2R1_Step4.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Adams, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelin, L. P.</span><span> </span><span class="NLM_article-title">Crystal structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide bound to d(CGTACG)2: implications for structure-activity relationships of acridinecarboxamide topoisomerase poisons</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=719-725&author=A.+Adamsauthor=J.+M.+Gussauthor=W.+A.+Dennyauthor=L.+P.+Wakelin&title=Crystal+structure+of+9-amino-N-%5B2-%284-morpholinyl%29ethyl%5D-4-acridinecarboxamide+bound+to+d%28CGTACG%292%3A+implications+for+structure-activity+relationships+of+acridinecarboxamide+topoisomerase+poisons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DA.%26aulast%3DGuss%26aufirst%3DJ.%2BM.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DWakelin%26aufirst%3DL.%2BP.%26atitle%3DCrystal%2520structure%2520of%25209-amino-N-%255B2-%25284-morpholinyl%2529ethyl%255D-4-acridinecarboxamide%2520bound%2520to%2520d%2528CGTACG%25292%253A%2520implications%2520for%2520structure-activity%2520relationships%2520of%2520acridinecarboxamide%2520topoisomerase%2520poisons%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2002%26volume%3D30%26spage%3D719%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Zang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, K. S.</span><span> </span><span class="NLM_article-title">DNA binding and alkylation by the “left half” of azinomycin B</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">14968</span><span class="NLM_x">–</span> <span class="NLM_lpage">14975</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi001998d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=14968-14975&author=H.+Zangauthor=K.+S.+Gates&title=DNA+binding+and+alkylation+by+the+%E2%80%9Cleft+half%E2%80%9D+of+azinomycin+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fbi001998d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi001998d%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DH.%26aulast%3DGates%26aufirst%3DK.%2BS.%26atitle%3DDNA%2520binding%2520and%2520alkylation%2520by%2520the%2520%25E2%2580%259Cleft%2520half%25E2%2580%259D%2520of%2520azinomycin%2520B%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D14968%26epage%3D14975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><div class="note"><p class="first last">Doxorubicin, a known intercalator, was titrated as a positve control for this assay. Structurally diverse Syk inhibitors were used as negative controls. See</p></div><span class="NLM_contrib-group">Northrup, A. B.; Altman, M. D.; Andresen, B. M.; Anthony, N. J.; Arrington, K. L.; Bhat, S.; Bienstock, C. E.; Black, C.; Burch, J.; Butcher, J. W.; Childers, K. K.; Cote, B.; Deschenes, D.; di Francesco, E.; Donofrio, A.; Ducharme, Y.; Dupont-Gaudet, K.; Ellis, J. M.; Fischer, C.; Fournier, J.-F.; Friesen, R.; Gauthier, J. Y.; Grimm, J. B.; Guay, D.; Guerin, D. J.; Haidle, A. M.; Jewell, J. P.; Kattar, S. D.; Li, C.; Lim, J.; Lee, S.; Liu, Y.; Machacek, M. R.; Maddess, M. L.; Miller, T. A.; O’Boyle, B. M.; Otte, R. D.; Peterson, S. L.; Petrocchi, A.; Reutershan, M. H.; Romeo, E. T.; Robichaud, J. S.; Schell, A. J.; Siu, T.; Smith, G. F.; Spencer, K. B.; Taoka, B. M.; Trotter, B. W.; Yang, L.; Woo, H. C.; Zhou, H.</span>Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, March 16–20, 2014; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>MEDI-36.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+B.+Northrup&author=M.+D.+Altman&author=B.+M.+Andresen&author=N.+J.+Anthony&author=K.+L.+Arrington&author=S.+Bhat&author=C.+E.+Bienstock&author=C.+Black&author=J.+Burch&author=J.+W.+Butcher&author=K.+K.+Childers&author=B.+Cote&author=D.+Deschenes&author=E.+di+Francesco&author=A.+Donofrio&author=Y.+Ducharme&author=K.+Dupont-Gaudet&author=J.+M.+Ellis&author=C.+Fischer&author=J.-F.+Fournier&author=R.+Friesen&author=J.+Y.+Gauthier&author=J.+B.+Grimm&author=D.+Guay&author=D.+J.+Guerin&author=A.+M.+Haidle&author=J.+P.+Jewell&author=S.+D.+Kattar&author=C.+Li&author=J.+Lim&author=S.+Lee&author=Y.+Liu&author=M.+R.+Machacek&author=M.+L.+Maddess&author=T.+A.+Miller&author=B.+M.+O%E2%80%99Boyle&author=R.+D.+Otte&author=S.+L.+Peterson&author=A.+Petrocchi&author=M.+H.+Reutershan&author=E.+T.+Romeo&author=J.+S.+Robichaud&author=A.+J.+Schell&author=T.+Siu&author=G.+F.+Smith&author=K.+B.+Spencer&author=B.+M.+Taoka&author=B.+W.+Trotter&author=L.+Yang&author=H.+C.+Woo&author=H.+Zhou&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DNorthrup%26aufirst%3DA.%2BB.%26jtitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="note"><p class="first last">All compounds tested to a top concentration of 406 μM DNA. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for further details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="note"><p class="first last">Ten of thirty compounds tested were negative in the UV–vis and bacterial mutagenicity assays.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="note"><p class="first last">A detailed account of the design principles applied to this scaffold redesign will be the subject of a future communication.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="note"><p class="first last">X-ray crystallograhpic data for the <i>C</i>-linked carboxamides will be detailed in a future communication.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="note"><p class="first last">We note that pyrazine <b>57</b> has not been tested in TA97a or the other strains used in the Ames bacterial mutagenicity assay.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="note"><p class="first last">The minimum surface area is the surface area of a sphere having a volume equal to the solvent-excluded volume of the molecule (computed from the Connolly molecular surface area and solvent-excluded volume properties).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':[],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':[],'ref38':[],'ref39':[],'ref40':[],'ref41':[],'ref42':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Christophe Fromont, Alessio Atzori, Divneet Kaur, Lubna Hashmi, Graziella Greco, Alejandro Cabanillas, Huy Van Nguyen, D. Heulyn Jones, Miguel Garzón, Ana Varela, Brett Stevenson, Greg P. Iacobini, Marc Lenoir, Sundaresan Rajesh, Clare Box, Jitendra Kumar, Paige Grant, Vera Novitskaya, Juliet Morgan, Fiona J. Sorrell, Clara Redondo, Andreas Kramer, C. John Harris, Brendan Leighton, Steven P. Vickers, Sharon C. Cheetham, Colin Kenyon, Anna M. Grabowska, Michael Overduin, Fedor Berditchevski, Chris J. Weston, Stefan Knapp, Peter M. Fischer, <span class="NLM_string-name hlFld-ContribAuthor">Sam Butterworth</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity in Vivo Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 6784-6801. <a href="https://doi.org/10.1021/acs.jmedchem.9b01803" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01803</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01803%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BHighly%252BSelective%252BInhibitors%252Bof%252BCalmodulin-Dependent%252BKinases%252BThat%252BRestore%252BInsulin%252BSensitivity%252Bin%252Bthe%252BDiet-Induced%252BObesity%252Bin%252BVivo%252BMouse%252BModel%26aulast%3DFromont%26aufirst%3DChristophe%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21012020%26date%3D22062020%26date%3D20052020%26volume%3D63%26issue%3D13%26spage%3D6784%26epage%3D6801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lewis D.  Pennington</span> and <span class="hlFld-ContribAuthor ">Demetri T.  Moustakas</span>  . </span><span class="cited-content_cbyCitation_article-title">The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (9)
                                     , 3552-3579. <a href="https://doi.org/10.1021/acs.jmedchem.6b01807" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01807%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BNecessary%252BNitrogen%252BAtom%25253A%252BA%252BVersatile%252BHigh-Impact%252BDesign%252BElement%252Bfor%252BMultiparameter%252BOptimization%26aulast%3DPennington%26aufirst%3DLewis%2BD.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D09122016%26date%3D08022017%26date%3D11052017%26volume%3D60%26issue%3D9%26spage%3D3552%26epage%3D3579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. Michael  Ellis</span>, <span class="hlFld-ContribAuthor ">Michael D.  Altman</span>, <span class="hlFld-ContribAuthor ">Brandon  Cash</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Haidle</span>, <span class="hlFld-ContribAuthor ">Rachel L.  Kubiak</span>, <span class="hlFld-ContribAuthor ">Matthew L.  Maddess</span>, <span class="hlFld-ContribAuthor ">Youwei  Yan</span>, and <span class="hlFld-ContribAuthor ">Alan B.  Northrup</span>  . </span><span class="cited-content_cbyCitation_article-title">Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (12)
                                     , 1151-1155. <a href="https://doi.org/10.1021/acsmedchemlett.6b00353" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00353</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00353%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCarboxamide%252BSpleen%252BTyrosine%252BKinase%252B%252528Syk%252529%252BInhibitors%25253A%252BLeveraging%252BGround%252BState%252BInteractions%252BTo%252BAccelerate%252BOptimization%26aulast%3DEllis%26aufirst%3DJ.%2BMichael%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D05092016%26date%3D07102016%26date%3D17102016%26date%3D08122016%26date%3D07102016%26volume%3D7%26issue%3D12%26spage%3D1151%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher R. M.  Asquith</span>, <span class="hlFld-ContribAuthor ">Tuomo  Laitinen</span>, <span class="hlFld-ContribAuthor ">James M.  Bennett</span>, <span class="hlFld-ContribAuthor ">Carrow I.  Wells</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Elkins</span>, <span class="hlFld-ContribAuthor ">William J.  Zuercher</span>, <span class="hlFld-ContribAuthor ">Graham J.  Tizzard</span>, <span class="hlFld-ContribAuthor ">Antti  Poso</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Analysis of the 4‐Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure‐Activity Relationships. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (1)
                                     , 26-49. <a href="https://doi.org/10.1002/cmdc.201900521" title="DOI URL">https://doi.org/10.1002/cmdc.201900521</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900521%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%252Band%252BAnalysis%252Bof%252Bthe%252B4%2525E2%252580%252590Anilinoquin%252528az%252529oline%252BKinase%252BInhibition%252BProfiles%252Bof%252BGAK%25252FSLK%25252FSTK10%252BUsing%252BQuantitative%252BStructure%2525E2%252580%252590Activity%252BRelationships%26aulast%3DAsquith%26aufirst%3DChristopher%2BR.%2BM.%26date%3D2020%26date%3D2019%26volume%3D15%26issue%3D1%26spage%3D26%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing  Wang</span>, <span class="hlFld-ContribAuthor ">Junfang  Guo</span>, <span class="hlFld-ContribAuthor ">Zhongqi  Ning</span>, <span class="hlFld-ContribAuthor ">Xia  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Natural Syk Inhibitor from Chinese Medicine through a Docking-Based Virtual Screening and Biological Assay Study. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (12)
                                     , 3114. <a href="https://doi.org/10.3390/molecules23123114" title="DOI URL">https://doi.org/10.3390/molecules23123114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23123114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23123114%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDiscovery%252Bof%252Ba%252BNatural%252BSyk%252BInhibitor%252Bfrom%252BChinese%252BMedicine%252Bthrough%252Ba%252BDocking-Based%252BVirtual%252BScreening%252Band%252BBiological%252BAssay%252BStudy%26aulast%3DWang%26aufirst%3DXing%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D12%26spage%3D3114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaokang  Li</span>, <span class="hlFld-ContribAuthor ">Yahui  Huang</span>, <span class="hlFld-ContribAuthor ">Junfei  Cheng</span>, <span class="hlFld-ContribAuthor ">Lingling  Zhang</span>, <span class="hlFld-ContribAuthor ">Fei  Mao</span>, <span class="hlFld-ContribAuthor ">Jin  Zhu</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel Syk/PDGFR-α/c-Kit inhibitors as multi-targeting drugs to treat rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (15)
                                     , 4375-4381. <a href="https://doi.org/10.1016/j.bmc.2018.06.029" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.06.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.06.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BSyk%25252FPDGFR-%2525CE%2525B1%25252Fc-Kit%252Binhibitors%252Bas%252Bmulti-targeting%252Bdrugs%252Bto%252Btreat%252Brheumatoid%252Barthritis%26aulast%3DLi%26aufirst%3DXiaokang%26date%3D2018%26volume%3D26%26issue%3D15%26spage%3D4375%26epage%3D4381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yahui  Huang</span>, <span class="hlFld-ContribAuthor ">Youjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Kexin  Fan</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Bohua  Li</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of new Syk inhibitors through structure-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (8)
                                     , 1776-1779. <a href="https://doi.org/10.1016/j.bmcl.2017.02.060" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.02.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.02.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.02.060%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnew%252BSyk%252Binhibitors%252Bthrough%252Bstructure-based%252Bvirtual%252Bscreening%26aulast%3DHuang%26aufirst%3DYahui%26date%3D2017%26volume%3D27%26issue%3D8%26spage%3D1776%26epage%3D1779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Remigijus  Didziapetris</span>, <span class="hlFld-ContribAuthor ">Kiril  Lanevskij</span>. </span><span class="cited-content_cbyCitation_article-title">Compilation and physicochemical classification analysis of a diverse hERG inhibition database. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2016,</strong> <em>30 </em>
                                    (12)
                                     , 1175-1188. <a href="https://doi.org/10.1007/s10822-016-9986-0" title="DOI URL">https://doi.org/10.1007/s10822-016-9986-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-016-9986-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-016-9986-0%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DCompilation%252Band%252Bphysicochemical%252Bclassification%252Banalysis%252Bof%252Ba%252Bdiverse%252BhERG%252Binhibition%252Bdatabase%26aulast%3DDidziapetris%26aufirst%3DRemigijus%26date%3D2016%26date%3D2016%26volume%3D30%26issue%3D12%26spage%3D1175%26epage%3D1188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Hoemann</span>, <span class="hlFld-ContribAuthor ">Noel  Wilson</span>, <span class="hlFld-ContribAuthor ">Maria  Argiriadi</span>, <span class="hlFld-ContribAuthor ">David  Banach</span>, <span class="hlFld-ContribAuthor ">Andrew  Burchat</span>, <span class="hlFld-ContribAuthor ">David  Calderwood</span>, <span class="hlFld-ContribAuthor ">Bruce  Clapham</span>, <span class="hlFld-ContribAuthor ">Phil  Cox</span>, <span class="hlFld-ContribAuthor ">David B.  Duignan</span>, <span class="hlFld-ContribAuthor ">Don  Konopacki</span>, <span class="hlFld-ContribAuthor ">Gagandeep  Somal</span>, <span class="hlFld-ContribAuthor ">Anil  Vasudevan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and optimization of furano[3,2- d ]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (22)
                                     , 5562-5567. <a href="https://doi.org/10.1016/j.bmcl.2016.09.077" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.09.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.09.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.09.077%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Boptimization%252Bof%252Bfurano%25255B3%25252C2-%252Bd%252B%25255Dpyrimidines%252Bas%252Bselective%252Bspleen%252Btyrosine%252Bkinase%252B%252528Syk%252529%252Binhibitors%26aulast%3DHoemann%26aufirst%3DMichael%26date%3D2016%26volume%3D26%26issue%3D22%26spage%3D5562%26epage%3D5567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiayi  Shen</span>, <span class="hlFld-ContribAuthor ">Xiaokai  Li</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jingfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Huoyou  Long</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Zhou</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>88 </em>
                                    (5)
                                     , 690-698. <a href="https://doi.org/10.1111/cbdd.12798" title="DOI URL">https://doi.org/10.1111/cbdd.12798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12798%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3D3-aminopyrazolopyrazine%252Bderivatives%252Bas%252Bspleen%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DShen%26aufirst%3DJiayi%26date%3D2016%26date%3D2016%26volume%3D88%26issue%3D5%26spage%3D690%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hideyuki  Igawa</span>, <span class="hlFld-ContribAuthor ">Masashi  Takahashi</span>, <span class="hlFld-ContribAuthor ">Minoru  Ikoma</span>, <span class="hlFld-ContribAuthor ">Hiromi  Kaku</span>, <span class="hlFld-ContribAuthor ">Keiko  Kakegawa</span>, <span class="hlFld-ContribAuthor ">Asato  Kina</span>, <span class="hlFld-ContribAuthor ">Jumpei  Aida</span>, <span class="hlFld-ContribAuthor ">Shoki  Okuda</span>, <span class="hlFld-ContribAuthor ">Yayoi  Kawata</span>, <span class="hlFld-ContribAuthor ">Toshihiro  Noguchi</span>, <span class="hlFld-ContribAuthor ">Natsu  Hotta</span>, <span class="hlFld-ContribAuthor ">Syunsuke  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Masaharu  Nakayama</span>, <span class="hlFld-ContribAuthor ">Yasutaka  Nagisa</span>, <span class="hlFld-ContribAuthor ">Shizuo  Kasai</span>, <span class="hlFld-ContribAuthor ">Tsuyoshi  Maekawa</span>. </span><span class="cited-content_cbyCitation_article-title">Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel non-basic 1-(2H-indazole-5-yl)pyridin-2(1H)-one derivatives and mitigation of mutagenicity in Ames test. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (11)
                                     , 2504-2518. <a href="https://doi.org/10.1016/j.bmc.2016.04.013" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.04.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.04.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAmine-free%252Bmelanin-concentrating%252Bhormone%252Breceptor%252B1%252Bantagonists%25253A%252BNovel%252Bnon-basic%252B1-%2525282H-indazole-5-yl%252529pyridin-2%2525281H%252529-one%252Bderivatives%252Band%252Bmitigation%252Bof%252Bmutagenicity%252Bin%252BAmes%252Btest%26aulast%3DIgawa%26aufirst%3DHideyuki%26date%3D2016%26volume%3D24%26issue%3D11%26spage%3D2504%26epage%3D2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven E.  McKenzie</span>. </span><span class="cited-content_cbyCitation_article-title">Syk Inhibition in Ischemic Stroke. </span><span class="cited-content_cbyCitation_journal-name">Arteriosclerosis, Thrombosis, and Vascular Biology</span><span> <strong>2016,</strong> <em>36 </em>
                                    (6)
                                     , 1054-1055. <a href="https://doi.org/10.1161/ATVBAHA.116.307709" title="DOI URL">https://doi.org/10.1161/ATVBAHA.116.307709</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1161/ATVBAHA.116.307709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1161%2FATVBAHA.116.307709%26sid%3Dliteratum%253Aachs%26jtitle%3DArteriosclerosis%252C%2520Thrombosis%252C%2520and%2520Vascular%2520Biology%26atitle%3DSyk%252BInhibition%252Bin%252BIschemic%252BStroke%26aulast%3DMcKenzie%26aufirst%3DSteven%2BE.%26date%3D2016%26volume%3D36%26issue%3D6%26spage%3D1054%26epage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. J.  Lamb</span>, <span class="hlFld-ContribAuthor ">S. L.  Wollin</span>, <span class="hlFld-ContribAuthor ">A.  Schnapp</span>, <span class="hlFld-ContribAuthor ">D.  Bischoff</span>, <span class="hlFld-ContribAuthor ">K. J.  Erb</span>, <span class="hlFld-ContribAuthor ">T.  Bouyssou</span>, <span class="hlFld-ContribAuthor ">B.  Guilliard</span>, <span class="hlFld-ContribAuthor ">C.  Strasser</span>, <span class="hlFld-ContribAuthor ">E.  Wex</span>, <span class="hlFld-ContribAuthor ">S.  Blum</span>, <span class="hlFld-ContribAuthor ">E.  Thaler</span>, <span class="hlFld-ContribAuthor ">H.  Nickel</span>, <span class="hlFld-ContribAuthor ">O.  Radmacher</span>, <span class="hlFld-ContribAuthor ">H.  Haas</span>, <span class="hlFld-ContribAuthor ">J. L.  Swantek</span>, <span class="hlFld-ContribAuthor ">D.  Souza</span>, <span class="hlFld-ContribAuthor ">M.  Canfield</span>, <span class="hlFld-ContribAuthor ">D.  White</span>, <span class="hlFld-ContribAuthor ">M.  Panzenbeck</span>, <span class="hlFld-ContribAuthor ">M. A.  Kashem</span>, <span class="hlFld-ContribAuthor ">M.  Sanville-Ross</span>, <span class="hlFld-ContribAuthor ">T.  Kono</span>, <span class="hlFld-ContribAuthor ">K.  Sewald</span>, <span class="hlFld-ContribAuthor ">A.  Braun</span>, <span class="hlFld-ContribAuthor ">H.  Obernolte</span>, <span class="hlFld-ContribAuthor ">O.  Danov</span>, <span class="hlFld-ContribAuthor ">G.  Schaenzle</span>, <span class="hlFld-ContribAuthor ">G.  Rast</span>, <span class="hlFld-ContribAuthor ">G.-M.  Maier</span>, <span class="hlFld-ContribAuthor ">M.  Hoffmann</span>. </span><span class="cited-content_cbyCitation_article-title">BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2016,</strong> <em>357 </em>
                                    (3)
                                     , 554-561. <a href="https://doi.org/10.1124/jpet.116.233155" title="DOI URL">https://doi.org/10.1124/jpet.116.233155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.116.233155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.116.233155%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DBI%252B1002494%25252C%252Ba%252BNovel%252BPotent%252Band%252BSelective%252BOral%252BSpleen%252BTyrosine%252BKinase%252BInhibitor%25252C%252BDisplays%252BDifferential%252BPotency%252Bin%252BHuman%252BBasophils%252Band%252BB%252BCells%26aulast%3DLamb%26aufirst%3DD.%2BJ.%26date%3D2016%26date%3D2016%26volume%3D357%26issue%3D3%26spage%3D554%26epage%3D561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gebhard  Thoma</span>, <span class="hlFld-ContribAuthor ">Siem  Veenstra</span>, <span class="hlFld-ContribAuthor ">Ross  Strang</span>, <span class="hlFld-ContribAuthor ">Joachim  Blanz</span>, <span class="hlFld-ContribAuthor ">Eric  Vangrevelinghe</span>, <span class="hlFld-ContribAuthor ">Jörg  Berghausen</span>, <span class="hlFld-ContribAuthor ">Christian C.  Lee</span>, <span class="hlFld-ContribAuthor ">Hans-Günter  Zerwes</span>. </span><span class="cited-content_cbyCitation_article-title">Orally bioavailable Syk inhibitors with activity in a rat PK/PD model. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (20)
                                     , 4642-4647. <a href="https://doi.org/10.1016/j.bmcl.2015.08.037" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.08.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.08.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOrally%252Bbioavailable%252BSyk%252Binhibitors%252Bwith%252Bactivity%252Bin%252Ba%252Brat%252BPK%25252FPD%252Bmodel%26aulast%3DThoma%26aufirst%3DGebhard%26date%3D2015%26volume%3D25%26issue%3D20%26spage%3D4642%26epage%3D4647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Diverse Syk inhibitor motifs from the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i>-Linked Heterocycles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) <i>tert</i>-Butyl [(1<i>S</i>,2<i>R</i>)-2-aminocyclohexyl]carbamate, DIEA, 110 °C; (b) 2-amino-4,6-dimethylpyridine, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C; (c) NaOH, 35% aq H<sub>2</sub>O<sub>2</sub>, DMSO, rt; (d) HCl, dioxane; (e) NH<sub>3</sub>, MeOH, rt.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Alternative Approach to the Synthesis of <i>N</i>-Linked Heterocycles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 2-Amino-4,6-dimethylpyridine, KO-<i>t</i>-Bu, THF, 0 °C; (b) <i>tert</i>-butyl (1-(aminomethyl)cyclopropyl)carbamate, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt (d) NaOH, 35% aq H<sub>2</sub>O<sub>2</sub>, DMSO, rt.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <i>C</i>-Linked Heterocycles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) <i>tert</i>-Butyl [(1<i>S</i>,2<i>R</i>)-2-aminocyclohexyl]carbamate, DIEA, 115 °C; (b) NIS, DMF, 65 °C; (c) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 120 °C; (d) 1<i>H</i>-indole-2-boronic acid pinacol ester, Pd(OAc)<sub>2</sub>, PCy<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, THF, 65 °C; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) KOH, 35% aq H<sub>2</sub>O<sub>2</sub>, DMSO, rt.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Rationale for intrinsic potency differences across cores.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Interaction of basic amine with Asp-512 for Syk potency and selectivity. X-ray cocrystal structure of YM-70220 in Syk (yellow) overlayed with AMP-PMP structure with Syk (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Rat collagen-induced arthritis efficacy of 3,5-diaminopicolinamide <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Physicochemical properties versus hERG ion channel activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Physicochemical properties versus hERG ion channel activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Profile of picolinamide <b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Initial compounds for mutagenicity assessment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Docking model of picolinamide <b>5</b> in DNA (from acridine/DNA cocrystals).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlay of <i>N</i>-linked carboxamide (<b>42</b>, red) with <i>C</i>-linked carboxamide (<b>56</b>, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/medium/jm-2014-018169_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0011.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Profile of pyrazine <b>57</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-4/jm5018169/20150220/images/large/jm-2014-018169_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018169&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64561" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64561" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Cohen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobburu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maung U, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staten, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=12006504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=935-942&author=M.+H.+Cohenauthor=G.+Williamsauthor=J.+R.+Johnsonauthor=J.+Duanauthor=J.+Gobburuauthor=A.+Rahmanauthor=K.+Bensonauthor=J.+Leightonauthor=S.+K.+Kimauthor=R.+Woodauthor=M.+Rothmannauthor=G.+Chenauthor=K.+Maung+Uauthor=A.+M.+Statenauthor=R.+Pazdur&title=Approval+summary+for+imatinib+mesylate+capsules+in+the+treatment+of+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span></div><div class="casAuthors">Cohen, Martin H.; Williams, Grant; Johnson, John R.; Duan, John; Gobburu, Jogarao; Rahman, Atiqur; Benson, Kimberly; Leighton, John; Kim, Sung K.; Wood, Rebecca; Rothmann, Mark; Chen, Gang; Maung U., Khin; Staten, Ann M.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">935-942</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) results from the breakpoint cluster region-Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis.  Imatinib, an orally administered inhibitor of the breakpoint cluster region-Abl tyrosine kinase, is capable of blocking proliferation and inducing apoptosis in CML cell lines.  In this report, we describe the preclin. profile of imatinib and the data submitted in the New Drug Application that led to its marketing approval.  Chem. manufg. and controls, animal toxicol., and biopharmaceutical data are described.  Results of Phase I and Phase II clin. studies in patients with CML in blast crisis (CML-BC), in accelerated phase (CML-AP), and in chronic phase disease-resistant or intolerant to IFN-α (CML-CP) are summarized.  The basis for marketing approval and postmarketing commitments by the pharmaceutical company are discussed.  Toxicol. studies in the rat, dog, and monkey show the hematol., renal, and hepatobiliary toxicity of imatinib.  Pharmacokinetic studies in patients with CML demonstrate 98% imatinib bioavailability.  The elimination half-lives of the parent drug and the major active metabolite, CGP74588, from plasma are approx. 18 and 40 h, resp.  Approx. 81% of the drug is eliminated in 7 days, 68% in the feces and 13% in the urine.  Cytochrome P 450 3A4 is the main enzyme responsible for imatinib metab.  Phase I and II clin. studies were conducted.  The Phase I study, in 83 CML patients, evaluated oral imatinib doses from 25 to 1000 mg/day.  Dose-limiting toxicity was not obsd.  The three Phase II studies, in CML-CP, CML-AP, and CML-BC, enrolled 1027 patients.  CML-CP patients received 400 mg/day imatinib, whereas CML-AP and CML-BC patients generally received 600 mg/day, imatinib.  Primary study endpoints were cytogenetic response rate (CML-CP) and hematol. response rate (CML-AP and CML-BC).  The cytogenetic response rate for CML-CP patients was 49%.  The hematol. response rate of CML-AP and CML-BC patients was 63 and 26%, resp.  The most common imatinib adverse events were nausea, vomiting, myalgia, edema, and diarrhea.  Elevated liver enzymes and/or bilirubin were reported in 27 patients (2.6%).  On May 10, 2001, imatinib mesylate (Gleevec, formerly known as STI-571 and Glivec), manufd. and distributed by Novartis Pharmaceuticals, East Hanover, NJ, was approved by the United States Food and Drug Administration for the treatment of CML in three clin. settings: CML-BC, CML-AP, and CML-CP.  This report summarizes the Food and Drug Administration's review of the New Drug Application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2majxsiqE3LVg90H21EOLACvtfcHk0liGIhGcbcHv1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D&md5=8820d9e1126524a6762242f68262ab86</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DBenson%26aufirst%3DK.%26aulast%3DLeighton%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DWood%26aufirst%3DR.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMaung%2BU%26aufirst%3DK.%26aulast%3DStaten%26aufirst%3DA.%2BM.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%2520for%2520imatinib%2520mesylate%2520capsules%2520in%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D935%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bonilla-Hernán, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda-Carús, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Mola, E.</span><span> </span><span class="NLM_article-title">New drugs beyond biologics in rheumatoid arthritis: The kinase inhibitors</span> <span class="citation_source-journal">Rheumatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">–</span> <span class="NLM_lpage">1550</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=1542-1550&author=M.+G.+Bonilla-Hern%C3%A1nauthor=M.+E.+Miranda-Car%C3%BAsauthor=E.+Martin-Mola&title=New+drugs+beyond+biologics+in+rheumatoid+arthritis%3A+The+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonilla-Hern%25C3%25A1n%26aufirst%3DM.%2BG.%26aulast%3DMiranda-Car%25C3%25BAs%26aufirst%3DM.%2BE.%26aulast%3DMartin-Mola%26aufirst%3DE.%26atitle%3DNew%2520drugs%2520beyond%2520biologics%2520in%2520rheumatoid%2520arthritis%253A%2520The%2520kinase%2520inhibitors%26jtitle%3DRheumatology%26date%3D2011%26volume%3D50%26spage%3D1542%26epage%3D1550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Müller-Ladner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pap, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gay, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gay, S.</span><span> </span><span class="NLM_article-title">Mechanisms of disease: The molecular and cellular basis of joint destruction in rheumatoid arthritis</span> <span class="citation_source-journal">J. Clin. Pract. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1038%2Fncprheum0047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=16932639" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=102-110&author=U.+M%C3%BCller-Ladnerauthor=T.+Papauthor=R.+E.+Gayauthor=M.+Neidhartauthor=S.+Gay&title=Mechanisms+of+disease%3A+The+molecular+and+cellular+basis+of+joint+destruction+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fncprheum0047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncprheum0047%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller-Ladner%26aufirst%3DU.%26aulast%3DPap%26aufirst%3DT.%26aulast%3DGay%26aufirst%3DR.%2BE.%26aulast%3DNeidhart%26aufirst%3DM.%26aulast%3DGay%26aufirst%3DS.%26atitle%3DMechanisms%2520of%2520disease%253A%2520The%2520molecular%2520and%2520cellular%2520basis%2520of%2520joint%2520destruction%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Pract.%2520Rheumatol.%26date%3D2005%26volume%3D1%26spage%3D102%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Filer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsonage, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curnow, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainger, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raza, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, C. D.</span><span> </span><span class="NLM_article-title">Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: Site-specific versus activation-dependent survival of T cells and neutrophils</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2096</span><span class="NLM_x">–</span> <span class="NLM_lpage">2108</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1002%2Fart.21930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=16802344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslKhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=2096-2108&author=A.+Filerauthor=G.+Parsonageauthor=E.+Smithauthor=C.+Osborneauthor=A.+M.+Thomasauthor=S.+J.+Curnowauthor=G.+E.+Raingerauthor=K.+Razaauthor=G.+B.+Nashauthor=J.+Lordauthor=M.+Salmonauthor=C.+D.+Buckley&title=Differential+survival+of+leukocyte+subsets+mediated+by+synovial%2C+bone+marrow%2C+and+skin+fibroblasts%3A+Site-specific+versus+activation-dependent+survival+of+T+cells+and+neutrophils"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils</span></div><div class="casAuthors">Filer, Andrew; Parsonage, Greg; Smith, Emily; Osborne, Chloe; Thomas, Andrew M. C.; Curnow, S. John; Rainger, G. Ed; Raza, Karim; Nash, Gerard B.; Lord, Janet; Salmon, Mike; Buckley, Christopher D.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2096-2108</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. Synovial fibroblasts share a no. of phenotype markers with fibroblasts derived from bone marrow.  In this study we investigated the role of matched fibroblasts obtained from 3 different sources (bone marrow, synovium, and skin) to test the hypothesis that synovial fibroblasts share similarities with bone marrow-derived fibroblasts in terms of their ability to support survival of T cells and neutrophils.  Methods. Matched synovial, bone marrow, and skin fibroblasts were established from 8 different patients with rheumatoid arthritis who were undergoing knee or hip surgery.  Resting or activated fibroblasts were cocultured with either CD4 T cells or neutrophils, and the degree of leukocyte survival, apoptosis, and proliferation were measured.  Results. Fibroblasts derived from all 3 sites supported increased survival of CD4 T cells, mediated principally by interferon-β.  However, synovial and bone marrow fibroblasts shared an enhanced site-specific ability to maintain CD4 T cell survival in the absence of proliferation, an effect that was independent of fibroblast activation or proliferation but required direct T cell-fibroblast cell contact.  In contrast, fibroblast-mediated neutrophil survival was less efficient, being independent of the site of origin of the fibroblast but dependent on prior fibroblast activation, and mediated solely by sol. factors, principally granulocyte-macrophage colony-stimulating factor.  Conclusion. These results suggest an important functional role for fibroblasts in the differential accumulation of leukocyte subsets in a variety of tissue microenvironments.  The findings also provide a potential explanation for site-specific differences in the pattern of T cell and neutrophil accumulation obsd. in chronic inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrztSfwzbAyvLVg90H21EOLACvtfcHk0liGIhGcbcHv1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslKhtbY%253D&md5=8c4565fcd9a1e7fa992f71a3c56ec0a2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fart.21930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.21930%26sid%3Dliteratum%253Aachs%26aulast%3DFiler%26aufirst%3DA.%26aulast%3DParsonage%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DA.%2BM.%26aulast%3DCurnow%26aufirst%3DS.%2BJ.%26aulast%3DRainger%26aufirst%3DG.%2BE.%26aulast%3DRaza%26aufirst%3DK.%26aulast%3DNash%26aufirst%3DG.%2BB.%26aulast%3DLord%26aufirst%3DJ.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DBuckley%26aufirst%3DC.%2BD.%26atitle%3DDifferential%2520survival%2520of%2520leukocyte%2520subsets%2520mediated%2520by%2520synovial%252C%2520bone%2520marrow%252C%2520and%2520skin%2520fibroblasts%253A%2520Site-specific%2520versus%2520activation-dependent%2520survival%2520of%2520T%2520cells%2520and%2520neutrophils%26jtitle%3DArthritis%2520Rheum.%26date%3D2006%26volume%3D54%26spage%3D2096%26epage%3D2108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Nimmerjahn, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravetch, J. V.</span><span> </span><span class="NLM_article-title">Fcγ receptors as regulators of immune responses</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1038%2Fnri2206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=18064051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKrsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=34-47&author=F.+Nimmerjahnauthor=J.+V.+Ravetch&title=Fc%CE%B3+receptors+as+regulators+of+immune+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fcγ receptors as regulators of immune responses</span></div><div class="casAuthors">Nimmerjahn, Falk; Ravetch, Jeffrey V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-47</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In addn. to their role in binding antigen, antibodies can regulate immune responses via interaction with Fc receptors (FcRs).  In recent years, significant progress has been made in understanding the mechanisms that regulate the activity of IgG antibodies in vivo.  Here, the authors discuss recent studies addressing the multifaceted roles of FcRs for IgG (FcγRs) in the immune system and how this knowledge could be translated into novel therapeutic strategies to treat human autoimmune, infectious or malignant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBbBMzHXrMsrVg90H21EOLACvtfcHk0lhHOw6QiejAAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKrsLnK&md5=dae5144e17b125fe8665944be2486783</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnri2206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2206%26sid%3Dliteratum%253Aachs%26aulast%3DNimmerjahn%26aufirst%3DF.%26aulast%3DRavetch%26aufirst%3DJ.%2BV.%26atitle%3DFc%25CE%25B3%2520receptors%2520as%2520regulators%2520of%2520immune%2520responses%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D34%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Burmester, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charles-Schoeman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollenhaupt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benda, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C.</span><span> </span><span class="NLM_article-title">Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">451</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=451-460&author=G.+R.+Burmesterauthor=R.+Blancoauthor=C.+Charles-Schoemanauthor=J.+Wollenhauptauthor=C.+Zerbiniauthor=B.+Bendaauthor=D.+Grubenauthor=G.+Wallensteinauthor=S.+Krishnaswamiauthor=S.+H.+Zwillichauthor=T.+Konczauthor=K.+Somaauthor=J.+Bradleyauthor=C.+Mebus&title=Tofacitinib+%28CP-690%2C550%29+in+combination+with+methotrexate+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+tumour+necrosis+factor+inhibitors%3A+A+randomised+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3DBlanco%26aufirst%3DR.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DZerbini%26aufirst%3DC.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DMebus%26aufirst%3DC.%26atitle%3DTofacitinib%2520%2528CP-690%252C550%2529%2520in%2520combination%2520with%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520tumour%2520necrosis%2520factor%2520inhibitors%253A%2520A%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D451%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Geahlen, R. L.</span><span> </span><span class="NLM_article-title">Getting Syk: Spleen tyrosine kinase as a therapeutic target</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=414-422&author=R.+L.+Geahlen&title=Getting+Syk%3A+Spleen+tyrosine+kinase+as+a+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeahlen%26aufirst%3DR.%2BL.%26atitle%3DGetting%2520Syk%253A%2520Spleen%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D414%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Mocsai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tybulewicz, V. L. J.</span><span> </span><span class="NLM_article-title">The Syk tyrosine kinase: A crucial player in diverse biological functions</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1038%2Fnri2765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=20467426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=387-402&author=A.+Mocsaiauthor=J.+Rulandauthor=V.+L.+J.+Tybulewicz&title=The+Syk+tyrosine+kinase%3A+A+crucial+player+in+diverse+biological+functions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The SYK tyrosine kinase: a crucial player in diverse biological functions</span></div><div class="casAuthors">Mocsai, Attila; Ruland, Jurgen; Tybulewicz, Victor L. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-402</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (SYK) is known to have a crucial role in adaptive immune receptor signalling.  However, recent reports indicate that SYK also mediates other, unexpectedly diverse biol. functions, including cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development.  SYK is activated by C-type lectins and integrins, and activates new targets, including the CARD9-BCL-10-MALT1 pathway and the NLRP3 inflammasome.  Studies using Drosophila melanogaster suggest that there is an evolutionarily ancient origin of SYK-mediated signalling.  Moreover, SYK has a crucial role in autoimmune diseases and haematol. malignancies.  This Review summarizes our current understanding of the diverse functions of SYK and how this is being translated for therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3YO5BcMqrf7Vg90H21EOLACvtfcHk0lhHOw6QiejAAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D&md5=85857a2b9beb84e0fe74263a90fa8a53</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnri2765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2765%26sid%3Dliteratum%253Aachs%26aulast%3DMocsai%26aufirst%3DA.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%2BJ.%26atitle%3DThe%2520Syk%2520tyrosine%2520kinase%253A%2520A%2520crucial%2520player%2520in%2520diverse%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26spage%3D387%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Pine, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoettler, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banquerigo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossbard, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahn, E.</span><span> </span><span class="NLM_article-title">Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1016%2Fj.clim.2007.03.543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=17537677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1eltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2007&pages=244-257&author=P.+R.+Pineauthor=B.+Changauthor=N.+Schoettlerauthor=M.+L.+Banquerigoauthor=S.+Wangauthor=A.+Lauauthor=F.+Zhaoauthor=E.+B.+Grossbardauthor=D.+G.+Payanauthor=E.+Brahn&title=Inflammation+and+bone+erosion+are+suppressed+in+models+of+rheumatoid+arthritis+following+treatment+with+a+novel+Syk+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor</span></div><div class="casAuthors">Pine, Polly R.; Chang, Betty; Schoettler, Nathan; Banquerigo, Mona L.; Wang, Su; Lau, Angela; Zhao, Feifei; Grossbard, Elliott B.; Payan, Donald G.; Brahn, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-257</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk), a key mediator of immunoreceptor signaling in inflammatory cells, is essential for immune complex-mediated signal transduction initiated by activated receptors for IgG.  In collagen-induced arthritis, R788/R406, a novel and potent small mol. Syk inhibitor suppressed clin. arthritis, bone erosions, pannus formation, and synovitis.  Serum anti-collagen type II antibody levels were unaltered, while the half-life of exogenous antibody was extended when co-administered with R406.  Expression of the targeted kinase (Syk) in synovial tissue correlated with the joint level of inflammatory cell infiltrates and was virtually undetectable in treated rats.  Syk inhibition suppressed synovial cytokines and cartilage oligomeric matrix protein (COMP) in serum, suggesting a sensitive and reliable biomarker for R406 activity.  These results highlight the role of activating Fcgamma receptors in inflammatory synovitis and suggest that interruption of the signaling cascade with a novel Syk inhibitor may be a useful addn. to immunosuppressive disease-modifying anti-rheumatic drugs currently used in the treatment of human autoimmune diseases such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Nm2XObIb37Vg90H21EOLACvtfcHk0lgbdOdG30XADQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1eltb0%253D&md5=98b5020fb23cc209e5b7c322024748fb</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2007.03.543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2007.03.543%26sid%3Dliteratum%253Aachs%26aulast%3DPine%26aufirst%3DP.%2BR.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DSchoettler%26aufirst%3DN.%26aulast%3DBanquerigo%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DBrahn%26aufirst%3DE.%26atitle%3DInflammation%2520and%2520bone%2520erosion%2520are%2520suppressed%2520in%2520models%2520of%2520rheumatoid%2520arthritis%2520following%2520treatment%2520with%2520a%2520novel%2520Syk%2520inhibitor%26jtitle%3DClin.%2520Immunol.%26date%3D2007%26volume%3D124%26spage%3D244%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Coffey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ives, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbach, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, U.</span><span> </span><span class="NLM_article-title">Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">350</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1124%2Fjpet.111.188441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=22040680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2012&pages=350-359&author=G.+Coffeyauthor=F.+DeGuzmanauthor=M.+Inagakiauthor=Y.+Pakauthor=S.+M.+Delaneyauthor=D.+Ivesauthor=A.+Betzauthor=Z.+J.+Jiaauthor=A.+Pandeyauthor=D.+Bakerauthor=S.+J.+Hollenbachauthor=D.+R.+Phillipsauthor=U.+Sinha&title=Specific+inhibition+of+spleen+tyrosine+kinase+suppresses+leukocyte+immune+function+and+inflammation+in+animal+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis</span></div><div class="casAuthors">Coffey, Greg; DeGuzman, Francis; Inagaki, Mayuko; Pak, Yvonne; Delaney, Suzanne M.; Ives, Dan; Betz, Andreas; Jia, Zhaozhong J.; Pandey, Anjali; Baker, Dale; Hollenbach, Stanley J.; Phillips, David R.; Sinha, Uma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">350-359</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Based on genetic studies that establish the role of spleen tyrosine kinase (Syk) in immune function, inhibitors of this kinase are being investigated as therapeutic agents for inflammatory diseases.  Because genetic studies eliminate both adapter functions and kinase activity of Syk, it is difficult to delineate the effect of kinase inhibition alone as would be the goal with small-mol. kinase inhibitors.  We tested the hypothesis that specific pharmacol. inhibition of Syk activity retains the immunomodulatory potential of Syk genetic deficiency.  We report here on the discovery of (4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino) pyrimidine-5-carboxamide acetate (P505-15), a highly specific and potent inhibitor of purified Syk (IC50 1-2 nM).  In human whole blood, P505-15 potently inhibited B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, resp.) and Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM).  Similar levels of ex vivo inhibition were measured after dosing in mice (Syk signaling IC50 0.32 μM).  Syk-independent signaling and activation were unaffected at much higher concns., demonstrating the specificity of kinase inhibition in cellular systems.  Oral administration of P505-15 produced dose-dependent anti-inflammatory activity in two rodent models of rheumatoid arthritis.  Statistically significant efficacy was obsd. at concns. that specifically suppressed Syk activity by ∼67%.  Thus specific Syk inhibition can mimic Syk genetic deficiency to modulate immune function, providing a therapeutic strategy in P505-15 for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNR__Bw5qSa7Vg90H21EOLACvtfcHk0lgbdOdG30XADQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSltL8%253D&md5=0f79a4c897abe6a25e873d02ee4fee4a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.188441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.188441%26sid%3Dliteratum%253Aachs%26aulast%3DCoffey%26aufirst%3DG.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DDelaney%26aufirst%3DS.%2BM.%26aulast%3DIves%26aufirst%3DD.%26aulast%3DBetz%26aufirst%3DA.%26aulast%3DJia%26aufirst%3DZ.%2BJ.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DHollenbach%26aufirst%3DS.%2BJ.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DSinha%26aufirst%3DU.%26atitle%3DSpecific%2520inhibition%2520of%2520spleen%2520tyrosine%2520kinase%2520suppresses%2520leukocyte%2520immune%2520function%2520and%2520inflammation%2520in%2520animal%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D340%26spage%3D350%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pashine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S.-L.</span><span> </span><span class="NLM_article-title">Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: Implications for SYK inhibitors in autoimmune disease therapy</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">R146</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=R146&author=C.+Liaoauthor=J.+Hsuauthor=Y.+Kimauthor=D.-Q.+Huauthor=D.+Xuauthor=J.+Zhangauthor=A.+Pashineauthor=J.+Menkeauthor=T.+Whittardauthor=N.+Romeroauthor=T.+Truittauthor=M.+Sladeauthor=C.+Lukacsauthor=J.+Hermannauthor=M.+Zhouauthor=M.+Lucasauthor=S.+Narulaauthor=J.+DeMartinoauthor=S.-L.+Tan&title=Selective+inhibition+of+spleen+tyrosine+kinase+%28SYK%29+with+a+novel+orally+bioavailable+small+molecule+inhibitor%2C+RO9021%2C+impinges+on+various+innate+and+adaptive+immune+responses%3A+Implications+for+SYK+inhibitors+in+autoimmune+disease+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DMenke%26aufirst%3DJ.%26aulast%3DWhittard%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DN.%26aulast%3DTruitt%26aufirst%3DT.%26aulast%3DSlade%26aufirst%3DM.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DHermann%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DM.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DS.-L.%26atitle%3DSelective%2520inhibition%2520of%2520spleen%2520tyrosine%2520kinase%2520%2528SYK%2529%2520with%2520a%2520novel%2520orally%2520bioavailable%2520small%2520molecule%2520inhibitor%252C%2520RO9021%252C%2520impinges%2520on%2520various%2520innate%2520and%2520adaptive%2520immune%2520responses%253A%2520Implications%2520for%2520SYK%2520inhibitors%2520in%2520autoimmune%2520disease%2520therapy%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2013%26volume%3D15%26spage%3DR146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Currie, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maclin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansdon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span> </span><span class="NLM_article-title">Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3856</span><span class="NLM_x">–</span> <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm500228a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3856-3873&author=K.+S.+Currieauthor=J.+E.+Kropfauthor=T.+Leeauthor=P.+Blomgrenauthor=J.+Xuauthor=Z.+Zhaoauthor=S.+Gallionauthor=J.+A.+Whitneyauthor=D.+Maclinauthor=E.+B.+Lansdonauthor=P.+Maciejewskiauthor=A.+M.+Rossiauthor=H.+Rongauthor=J.+Macalusoauthor=J.+Barbosaauthor=J.+A.+Di+Paoloauthor=S.+A.+Mitchell&title=Discovery+of+GS-9973%2C+a+selective+and+orally+efficacious+inhibitor+of+spleen+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm500228a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500228a%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DMaclin%26aufirst%3DD.%26aulast%3DLansdon%26aufirst%3DE.%2BB.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26atitle%3DDiscovery%2520of%2520GS-9973%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520spleen%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3856%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Weinblatt, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavanaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musser, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossbard, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magilavy, D. B.</span><span> </span><span class="NLM_article-title">Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">378</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.3899%2Fjrheum.120923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=23378467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12qs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=369-378&author=M.+E.+Weinblattauthor=A.+Kavanaughauthor=M.+C.+Genoveseauthor=D.+A.+Jonesauthor=T.+K.+Musserauthor=E.+B.+Grossbardauthor=D.+B.+Magilavy&title=Effects+of+fostamatinib+%28R788%29%2C+an+oral+spleen+tyrosine+kinase+inhibitor%2C+on+health-related+quality+of+life+in+patients+with+active+rheumatoid+arthritis%3A+analyses+of+patient-reported+outcomes+from+a+randomized%2C+double-blind%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Weinblatt, Michael E.; Kavanaugh, Arthur; Genovese, Mark C.; Jones, David A.; Musser, Theresa K.; Grossbard, Elliott B.; Magilavy, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-378</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective. To assess the influence of fostamatinib on patient-reported outcomes (PRO) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX).  Methods. Patients taking background MTX (N = 457) were enrolled in a phase II clin. trial (NCT00665925) and randomized equally to placebo, fostamatinib 100 mg twice daily (bid), or fostamatinib 150 mg once daily (qd) for 24 wk.  Self-administered PRO measures included pain, patient's global assessment (PtGA) of disease activity, phys. function, health-related quality of life (HRQOL), and fatigue.  Mean change from baseline and a responder anal. of the proportion of patients achieving a minimal clin. important difference were detd.  Results. At Week 24, there were statistically significant improvements in pain, PtGA, phys. function, fatigue, and the phys. component summary of the Medical Outcomes Study Short Form-36 (SF-36) for fostamatinib 100 mg bid compared with placebo.  Mean (std. error) changes from baseline in the fostamatinib 100 mg bid group vs. the placebo group were -31.3 (2.45) vs. -17.8 (2.45), p < 0.001 for pain; -29.1 (2.26) vs. -16.7 (2.42), p < 0.001 for PtGA; -0.647 (0.064) vs. -0.343 (0.062), p < 0.001 for phys. function; 7.40 (1.00) vs. 4.50 (0.94), p < 0.05 for fatigue; 8.52 (0.77) vs. 4.90 (0.78), p < 0.01 for SF-36 phys. component score; and 3.99 (0.93) vs. 3.71 (0.99), p = 0.83 for SF-36 mental component score.  Patients receiving fostamatinib 150 mg qd showed improvements in some PRO, including phys. function.  Conclusion. Patients treated with fostamatinib 100 mg bid showed significant improvements in HRQOL outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIPy0NRTaLcLVg90H21EOLACvtfcHk0lj6iqn-p46aeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12qs7s%253D&md5=830c76d39d46e7ffa679a5530d80bc50</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.120923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.120923%26sid%3Dliteratum%253Aachs%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DJones%26aufirst%3DD.%2BA.%26aulast%3DMusser%26aufirst%3DT.%2BK.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DMagilavy%26aufirst%3DD.%2BB.%26atitle%3DEffects%2520of%2520fostamatinib%2520%2528R788%2529%252C%2520an%2520oral%2520spleen%2520tyrosine%2520kinase%2520inhibitor%252C%2520on%2520health-related%2520quality%2520of%2520life%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520analyses%2520of%2520patient-reported%2520outcomes%2520from%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Rheumatol.%26date%3D2013%26volume%3D40%26spage%3D369%26epage%3D378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Edwards, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczepanski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szechinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipowicz-Sosnowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Close, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, T.</span><span> </span><span class="NLM_article-title">Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2572</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1056%2FNEJMoa032534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=15201414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFKntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2572-81&author=J.+Edwardsauthor=L.+Szczepanskiauthor=J.+Szechinskiauthor=A.+Filipowicz-Sosnowskaauthor=P.+Emeryauthor=D.+Closeauthor=R.+Stevensauthor=T.+Shaw&title=Efficacy+of+B-cell-targeted+therapy+with+rituximab+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis</span></div><div class="casAuthors">Edwards, Jonathan C. W.; Szczepanski, Leszek; Szechinski, Jacek; Filipowicz-Sosnowska, Anna; Emery, Paul; Close, David R.; Stevens, Randall M.; Shaw, Tim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2572-2581</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clin. improvements for patients with rheumatoid arthritis.  To confirm these observations, we conducted a randomized, double-blind, controlled study.  We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (≥10 mgper week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate.  Responses defined according to the criteria of the American College of Rheumatol. (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses).  At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent).  In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P≤0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P≤0.004).  All ACRresponses were maintained at week 48 in the rituximab-methotrexate group.  The majority of adverse events occurred with the first rituximab infusion: at 24 wk, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups.  Peripheral-blood Ig concns. remained within normal ranges.  In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1mDg3P-3cC7Vg90H21EOLACvtfcHk0lj6iqn-p46aeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFKntrc%253D&md5=3b8abe2027557b0733fc5d81d28965f7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032534%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DJ.%26aulast%3DSzczepanski%26aufirst%3DL.%26aulast%3DSzechinski%26aufirst%3DJ.%26aulast%3DFilipowicz-Sosnowska%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DP.%26aulast%3DClose%26aufirst%3DD.%26aulast%3DStevens%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DT.%26atitle%3DEfficacy%2520of%2520B-cell-targeted%2520therapy%2520with%2520rituximab%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2572%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><div class="note"><p class="first last">For the role of VEGF inhibition in hypertension see:</p></div><span class="NLM_contrib-group">Pande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangethal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javle, M.</span><span> </span><span class="NLM_article-title">Hypertension secondary to anti-angiogenic therapy: Experience with bevacizumab</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3465</span><span class="NLM_x">–</span> <span class="NLM_lpage">3470</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=17972502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWjs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=3465-3470&author=A.+Pandeauthor=J.+Lombardoauthor=E.+Spangethalauthor=M.+Javle&title=Hypertension+secondary+to+anti-angiogenic+therapy%3A+Experience+with+bevacizumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab</span></div><div class="casAuthors">Pande, Amitkumar; Lombardo, Jeffrey; Spangenthal, Edward; Javle, Milind</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5B</span>),
    <span class="NLM_cas:pages">3465-3470</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Hypertension (HT) is a common complication of anti-angiogenic therapy.  Its incidence, treatment and complications are undefined.  Patients and Methods: Retrospective review of patients treated with bevacizumab (BV) from 2003-5.  Common toxicity criteria (CTC) for adverse events version 3.0 were used.  Results: Fifty-five out of the 154 patients treated with BV (35%) experienced HT.  Eleven (20%) developed a new onset HT and 44 (80%) experienced an exacerbation of pre-existing HT.  HT developed after a median of 11 wk at a median BV dose of 10 mg/kg.  HT severity was grade 1 (n = 1), grade 2 (n = 29) or grade 3 (n = 22); 3 experienced hypertensive complications.  HT was controlled in 47 (85%); BV was discontinued in 3.  The angiotensin-converting enzyme inhibitor (ACE-I), quinapril was commonly used and resulted in better HT control than ACE-II, calcium channel or beta antagonists.  Conclusion: HT assocd. with bevacizumab therapy is a manageable toxicity with the use of ACE-I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqvYpPYDdty7Vg90H21EOLACvtfcHk0lj6iqn-p46aeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWjs7zK&md5=9ed49f6d9626ebc0ee3d39de5740b22c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPande%26aufirst%3DA.%26aulast%3DLombardo%26aufirst%3DJ.%26aulast%3DSpangethal%26aufirst%3DE.%26aulast%3DJavle%26aufirst%3DM.%26atitle%3DHypertension%2520secondary%2520to%2520anti-angiogenic%2520therapy%253A%2520Experience%2520with%2520bevacizumab%26jtitle%3DAnticancer%2520Res.%26date%3D2007%26volume%3D27%26spage%3D3465%26epage%3D3470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Suljagic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennardo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efremov, D. G.</span><span> </span><span class="NLM_article-title">The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">4894</span><span class="NLM_x">–</span> <span class="NLM_lpage">4905</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4894-4905&author=M.+Suljagicauthor=P.+G.+Longoauthor=S.+Bennardoauthor=E.+Perlasauthor=G.+Leoneauthor=L.+Laurentiauthor=D.+G.+Efremov&title=The+Syk+inhibitor+fostamatinib+disodium+%28R788%29+inhibits+tumor+growth+in+the+E%CE%BC-TCL1+transgenic+mouse+model+of+CLL+by+blocking+antigen-dependent+B-cell+receptor+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuljagic%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DP.%2BG.%26aulast%3DBennardo%26aufirst%3DS.%26aulast%3DPerlas%26aufirst%3DE.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DLaurenti%26aufirst%3DL.%26aulast%3DEfremov%26aufirst%3DD.%2BG.%26atitle%3DThe%2520Syk%2520inhibitor%2520fostamatinib%2520disodium%2520%2528R788%2529%2520inhibits%2520tumor%2520growth%2520in%2520the%2520E%25CE%25BC-TCL1%2520transgenic%2520mouse%2520model%2520of%2520CLL%2520by%2520blocking%2520antigen-dependent%2520B-cell%2520receptor%2520signaling%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D4894%26epage%3D4905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Friedberg, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweetenham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vose, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacasce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer-Cutillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cripe, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterba, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipp, M. A.</span><span> </span><span class="NLM_article-title">Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2578</span><span class="NLM_x">–</span> <span class="NLM_lpage">2585</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=2578-2585&author=J.+W.+Friedbergauthor=J.+Sharmanauthor=J.+Sweetenhamauthor=P.+B.+Johnstonauthor=J.+M.+Voseauthor=A.+Lacasceauthor=J.+Schaefer-Cutilloauthor=S.+De+Vosauthor=R.+Sinhaauthor=J.+P.+Leonardauthor=L.+D.+Cripeauthor=S.+A.+Gregoryauthor=M.+P.+Sterbaauthor=A.+M.+Loweauthor=R.+Levyauthor=M.+A.+Shipp&title=Inhibition+of+Syk+with+fostamatinib+disodium+has+significant+clinical+activity+in+non-Hodgkin+lymphoma+and+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFriedberg%26aufirst%3DJ.%2BW.%26aulast%3DSharman%26aufirst%3DJ.%26aulast%3DSweetenham%26aufirst%3DJ.%26aulast%3DJohnston%26aufirst%3DP.%2BB.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DLacasce%26aufirst%3DA.%26aulast%3DSchaefer-Cutillo%26aufirst%3DJ.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DLeonard%26aufirst%3DJ.%2BP.%26aulast%3DCripe%26aufirst%3DL.%2BD.%26aulast%3DGregory%26aufirst%3DS.%2BA.%26aulast%3DSterba%26aufirst%3DM.%2BP.%26aulast%3DLowe%26aufirst%3DA.%2BM.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DShipp%26aufirst%3DM.%2BA.%26atitle%3DInhibition%2520of%2520Syk%2520with%2520fostamatinib%2520disodium%2520has%2520significant%2520clinical%2520activity%2520in%2520non-Hodgkin%2520lymphoma%2520and%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D2578%26epage%3D2585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ulanova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puttagunta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Befus, A. D.</span><span> </span><span class="NLM_article-title">Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">901</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1517%2F14728222.9.5.901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=16185147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVartbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=901-921&author=M.+Ulanovaauthor=F.+Dutaauthor=L.+Puttaguntaauthor=A.+D.+Schreiberauthor=A.+D.+Befus&title=Spleen+tyrosine+kinase+%28Syk%29+as+a+novel+target+for+allergic+asthma+and+rhinitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis</span></div><div class="casAuthors">Ulanova, Marina; Duta, Florentina; Puttagunta, Lakshmi; Schreiber, Alan D.; Befus, A. Dean</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">901-921</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Allergic asthma and rhinitis are prevalent diseases in the modern world, both marked by inflammation of the airways.  The spleen tyrosine kinase (Syk) plays a crit. role in the regulation of such immune and inflammatory responses.  Although Syk is best known as a key component of immunoreceptor signaling complexes in leukocytes, recent studies demonstrated Syk expression in cells outside the haematopoietic lineage.  Moreover, in recent years, it has been established that Syk is involved in various signaling cascades including those originating from integrin and cytokine receptors.  Thus, Syk likely has a much wider biol. role than previously recognized.  Specific inhibition of Syk using aerosolised antisense oligonucleotides in liposome complexes significantly decreased lung inflammatory responses in exptl. asthma and acute lung injury models.  In addn., pharmacol. inhibitors of Syk have been recently developed with potential for use as therapeutics.  However, in the development and the rational delivery of drugs targeting Syk, it is important to consider the multiple cell types that express this kinase and the potential effects of its inhibition on various physiol. functions.  This review focuses on the recent data and the emerging ideas about Syk as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5sKbhtE4OO7Vg90H21EOLACvtfcHk0lg2VK5cVJGW7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVartbbJ&md5=8cb1ce3346dabd9ffa4a8d380746f5b5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F14728222.9.5.901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.9.5.901%26sid%3Dliteratum%253Aachs%26aulast%3DUlanova%26aufirst%3DM.%26aulast%3DDuta%26aufirst%3DF.%26aulast%3DPuttagunta%26aufirst%3DL.%26aulast%3DSchreiber%26aufirst%3DA.%2BD.%26aulast%3DBefus%26aufirst%3DA.%2BD.%26atitle%3DSpleen%2520tyrosine%2520kinase%2520%2528Syk%2529%2520as%2520a%2520novel%2520target%2520for%2520allergic%2520asthma%2520and%2520rhinitis%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2005%26volume%3D9%26spage%3D901%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Moy, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caniga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieber, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirkowski, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northrup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houshyar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackower, M. A.</span><span> </span><span class="NLM_article-title">Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1165%2Frcmb.2013-0200OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=23889698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyhu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=1085-1092&author=L.+Y.+Moyauthor=Y.+Jiaauthor=M.+Canigaauthor=G.+Lieberauthor=M.+Gilauthor=X.+Fernandezauthor=E.+Sirkowskiauthor=R.+Millerauthor=J.+P.+Alexanderauthor=H.-H.+Leeauthor=J.+D.+Shinauthor=J.+M.+Ellisauthor=H.+Chenauthor=A.+Wilhelmauthor=H.+Yuauthor=S.+Vincentauthor=R.+W.+Chapmanauthor=N.+Kellyauthor=E.+Hickeyauthor=W.+M.+Abrahamauthor=A.+Northrupauthor=T.+Millerauthor=H.+Houshyarauthor=M.+A.+Crackower&title=Inhibition+of+spleen+tyrosine+kinase+attenuates+allergen-mediated+airway+constriction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction</span></div><div class="casAuthors">Moy, Lily Y.; Jia, Yanlin; Caniga, Michael; Lieber, Gissela; Gil, Malgorzata; Fernandez, Xiomara; Sirkowski, Erich; Miller, Richard; Alexander, Jessica P.; Lee, Hyun-Hee; Shin, John D.; Ellis, J. Michael; Chen, Hongmin; Wilhelm, Alan; Yu, Hongshi; Vincent, Stella; Chapman, Richard W.; Kelly, Nancy; Hickey, Emily; Abraham, William M.; Northrup, Alan; Miller, Thomas; Houshyar, Hani; Crackower, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (SYK) is a key activator of signaling pathways downstream of multiple surface receptors implicated in asthma.  SYK function has been extensively studied in mast cells downstream of the high-affinity IgE receptor, FcεR1.  Preclin. studies have demonstrated a role for SYK in models of allergic inflammation, but a role in airway constriction has not been demonstrated.  Here, we have used a potent and selective pharmacol. inhibitor of SYK to det. the role of SYK in allergen-mediated inflammation and airway constriction in preclin. models.  Attenuation of allergic airway responses was evaluated in a rat passive anaphylaxis model and rat and sheep inhaled allergen challenge models, as well as an ex vivo model of allergen-mediated airway constriction in rats and cynomolgus monkeys.  Pharmacol. inhibition of SYK dose-dependently blocked IgE-mediated tracheal plasma extravasation in rats.  In a rat ovalbumin-sensitized airway challenge model, oral dosing with an SYK inhibitor led to a dose-dependent redn. in lung inflammatory cells.  Ex vivo anal. of allergen-induced airway constriction in ovalbumin-sensitized brown Norway rats showed a complete attenuation with treatment of a SYK inhibitor, as well as a complete block of allergen-induced serotonin release.  Similarly, allergen-mediated airway constriction was attenuated in ex vivo studies from nonhuman primate lungs.  I.v. administration of an SYK inhibitor attenuated both early- and late-phase allergen-induced increases in airway resistance in an Ascaris-sensitive sheep allergen challenge model.  These data support a key role for SYK signaling in mediating allergic airway responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh2FAd7eonHLVg90H21EOLACvtfcHk0lg2VK5cVJGW7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyhu7fF&md5=8091e1196bdce7352838f5ef9d699f42</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2013-0200OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2013-0200OC%26sid%3Dliteratum%253Aachs%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DCaniga%26aufirst%3DM.%26aulast%3DLieber%26aufirst%3DG.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DX.%26aulast%3DSirkowski%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DAlexander%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DShin%26aufirst%3DJ.%2BD.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWilhelm%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DS.%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DKelly%26aufirst%3DN.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DAbraham%26aufirst%3DW.%2BM.%26aulast%3DNorthrup%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DHoushyar%26aufirst%3DH.%26aulast%3DCrackower%26aufirst%3DM.%2BA.%26atitle%3DInhibition%2520of%2520spleen%2520tyrosine%2520kinase%2520attenuates%2520allergen-mediated%2520airway%2520constriction%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2013%26volume%3D49%26spage%3D1085%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Surry, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Dialkylbiaryl phosphines in Pd-catalyzed amination: A user’s guide</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1039%2Fc0sc00331j" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=27-50&author=D.+S.+Surryauthor=S.+L.+Buchwald&title=Dialkylbiaryl+phosphines+in+Pd-catalyzed+amination%3A+A+user%E2%80%99s+guide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dialkylbiaryl phosphines in Pd-catalyzed amination: a user's guide</span></div><div class="casAuthors">Surry, David S.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-50</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Dialkylbiaryl phosphines are a valuable class of ligand for Pd-catalyzed amination reactions and have been applied in a range of contexts.  This perspective attempts to aid the reader in the selection of the best choice of reaction conditions and ligand of this class for the most commonly encountered and practically important substrate combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0vbHHdx-_rVg90H21EOLACvtfcHk0lgiTUT_eh7L8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbnM&md5=8743358f11af138189d106c51b5942b9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc0sc00331j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0sc00331j%26sid%3Dliteratum%253Aachs%26aulast%3DSurry%26aufirst%3DD.%2BS.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DDialkylbiaryl%2520phosphines%2520in%2520Pd-catalyzed%2520amination%253A%2520A%2520user%25E2%2580%2599s%2520guide%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26spage%3D27%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Miyaura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3437</span><span class="NLM_x">–</span> <span class="NLM_lpage">3440</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1979&pages=3437-3440&author=N.+Miyauraauthor=K.+Yamadaauthor=A.+Suzuki&title=A+new+stereospecific+cross-coupling+by+the+palladium-catalyzed+reaction+of+1-alkenylboranes+with+1-alkenyl+or+1-alkynyl+halides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DA%2520new%2520stereospecific%2520cross-coupling%2520by%2520the%2520palladium-catalyzed%2520reaction%2520of%25201-alkenylboranes%2520with%25201-alkenyl%2520or%25201-alkynyl%2520halides%26jtitle%3DTetrahedron%2520Lett.%26date%3D1979%26volume%3D36%26spage%3D3437%26epage%3D3440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Hisamichi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoshima, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span> </span><span class="NLM_article-title">Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4936</span><span class="NLM_x">–</span> <span class="NLM_lpage">4951</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=4936-4951&author=H.+Hisamichiauthor=R.+Naitoauthor=A.+Toyoshimaauthor=N.+Kawanoauthor=A.+Ichikawaauthor=A.+Oritaauthor=M.+Oritaauthor=N.+Hamadaauthor=M.+Takeuchiauthor=M.+Ohtaauthor=S.+Tsukamoto&title=Synthetic+studies+on+novel+Syk+inhibitors.+Part+1%3A+Synthesis+and+structure-activity+relationships+of+pyrimidine-5-carboxamide+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHisamichi%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DR.%26aulast%3DToyoshima%26aufirst%3DA.%26aulast%3DKawano%26aufirst%3DN.%26aulast%3DIchikawa%26aufirst%3DA.%26aulast%3DOrita%26aufirst%3DA.%26aulast%3DOrita%26aufirst%3DM.%26aulast%3DHamada%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%26atitle%3DSynthetic%2520studies%2520on%2520novel%2520Syk%2520inhibitors.%2520Part%25201%253A%2520Synthesis%2520and%2520structure-activity%2520relationships%2520of%2520pyrimidine-5-carboxamide%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D4936%26epage%3D4951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span> </span><span class="NLM_article-title">Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=466-470&author=A.+G.+Villasenorauthor=R.+Kendraauthor=H.+Hoauthor=S.+Wangauthor=E.+Pappauthor=D.+Shawauthor=J.+W.+Barnettauthor=M.+F.+Brownerauthor=A.+Kuglstatter&title=Structural+insights+for+design+of+potent+spleen+tyrosine+kinase+inhibitors+from+crystallographic+analysis+of+three+inhibitor+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DKendra%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPapp%26aufirst%3DE.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26aulast%3DKuglstatter%26aufirst%3DA.%26atitle%3DStructural%2520insights%2520for%2520design%2520of%2520potent%2520spleen%2520tyrosine%2520kinase%2520inhibitors%2520from%2520crystallographic%2520analysis%2520of%2520three%2520inhibitor%2520complexes%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D73%26spage%3D466%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleo, M. D.</span><span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+A+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0lihtNjc228Bhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520A%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><div class="note"><p class="first last">Data for pyridazinecarboxamide <b>21</b> from</p></div><span class="NLM_contrib-group">Lucas, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagirath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiao, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy-Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padilla, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polonchuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Railkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadava, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span> </span><span class="NLM_article-title">Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2683</span><span class="NLM_x">–</span> <span class="NLM_lpage">2691</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401982j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2683-2691&author=M.+C.+Lucasauthor=N.+Bhagirathauthor=E.+Chiaoauthor=D.+M.+Goldsteinauthor=J.+C.+Hermannauthor=P.-Y.+Hsuauthor=S.+Kirchnerauthor=J.+J.+Kennedy-Smithauthor=A.+Kuglstatterauthor=C.+Lukacsauthor=J.+Menkeauthor=L.+Niuauthor=F.+Padillaauthor=Y.+Pengauthor=L.+Polonchukauthor=A.+Railkarauthor=M.+Sladeauthor=M.+Sothauthor=D.+Xuauthor=P.+Yadavaauthor=C.+Yeeauthor=M.+Zhouauthor=C.+Liao&title=Using+ovality+to+predict+nonmutagenic%2C+orally+efficacious+pyridazine+amides+as+cell+specific+spleen+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm401982j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401982j%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DBhagirath%26aufirst%3DN.%26aulast%3DChiao%26aufirst%3DE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHermann%26aufirst%3DJ.%2BC.%26aulast%3DHsu%26aufirst%3DP.-Y.%26aulast%3DKirchner%26aufirst%3DS.%26aulast%3DKennedy-Smith%26aufirst%3DJ.%2BJ.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DMenke%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DPadilla%26aufirst%3DF.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DPolonchuk%26aufirst%3DL.%26aulast%3DRailkar%26aufirst%3DA.%26aulast%3DSlade%26aufirst%3DM.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DYadava%26aufirst%3DP.%26aulast%3DYee%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DC.%26atitle%3DUsing%2520ovality%2520to%2520predict%2520nonmutagenic%252C%2520orally%2520efficacious%2520pyridazine%2520amides%2520as%2520cell%2520specific%2520spleen%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2683%26epage%3D2691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">This level of Zap70 versus Syk enzymatic selectivity was generally maintained for all carboxamides.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span> </span><span class="NLM_article-title">Drug-like properties and the causes of poor solubility and poor permeability</span> <span class="citation_source-journal">J. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm5018169&amp;key=10.1016%2FS1056-8719%2800%2900107-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm5018169&amp;key=11274893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A280%3ADC%252BD3M7os1OjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=235-249&author=C.+A.+Lipinski&title=Drug-like+properties+and+the+causes+of+poor+solubility+and+poor+permeability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-like properties and the causes of poor solubility and poor permeability</span></div><div class="casAuthors">Lipinski C A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacological and toxicological methods</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-49</span>
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    </div><div class="casAbstract">There are currently about 10000 drug-like compounds.  These are sparsely, rather than uniformly, distributed through chemistry space.  True diversity does not exist in experimental combinatorial chemistry screening libraries.  Absorption, distribution, metabolism, and excretion (ADME) and chemical reactivity-related toxicity is low, while biological receptor activity is higher dimensional in chemistry space, and this is partly explainable by evolutionary pressures on ADME to deal with endobiotics and exobiotics.  ADME is hard to predict for large data sets because current ADME experimental screens are multi-mechanisms, and predictions get worse as more data accumulates.  Currently, screening for biological receptor activity precedes or is concurrent with screening for properties related to "drugability." In the future, "drugability" screening may precede biological receptor activity screening.  The level of permeability or solubility needed for oral absorption is related to potency.  The relative importance of poor solubility and poor permeability towards the problem of poor oral absorption depends on the research approach used for lead generation.  A "rational drug design" approach as exemplified by Merck advanced clinical candidates leads to time-dependent higher molecular weight, higher H-bonding properties, unchanged lipophilicity, and, hence, poorer permeability.  A high throughput screening (HTS)-based approach as exemplified by unpublished data on Pfizer (Groton, CT) early candidates leads to higher molecular weight, unchanged H-bonding properties, higher lipophilicity, and, hence, poorer aqueous solubility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmUcEou3dTa_EeosoOnpOLfW6udTcc2eZcsYZwxAqGP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7os1OjsQ%253D%253D&md5=aeb705afe1eccaceaf441c7a19f13ecc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2800%2900107-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252800%252900107-6%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DDrug-like%2520properties%2520and%2520the%2520causes%2520of%2520poor%2520solubility%2520and%2520poor%2520permeability%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%26date%3D2000%26volume%3D44%26spage%3D235%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm5018169&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lg_B0O1ZKnleg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Penna, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karczewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span> </span><span class="NLM_article-title">Functional and pharmacological properties of canine ERG potassium channels</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=256-267&author=J.+Wangauthor=K.+Della+Pennaauthor=H.+Wangauthor=J.+Karczewskiauthor=T.+M.+Connollyauthor=K.+S.+Koblanauthor=P.+B.+Bennettauthor=J.+J.+Salata&title=Functional+and+pharmacological+properties+of+canine+ERG+potassium+channels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDella%2BPenna%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKarczewski%26aufirst%3DJ.%26aulast%3DConnolly%26aufirst%3DT.%2BM.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DBennett%26aufirst%3DP.%2BB.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26atitle%3DFunctional%2520and%2520pharmacological%2520properties%2520of%2520canine%2520ERG%2520potassium%2520channels%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D2003%26volume%3D284%26spage%3D256%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><div class="note"><p class="first last">Higher throughput binding assay measures displacement of MK-499, a strong binder to the hERG ion channel.</p></div><span class="NLM_contrib-group">Priest, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. L.</span><span> </span><span class="NLM_article-title">Role of hERG potassium channel assays in drug development</span> <span class="citation_source-journal">Channels</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=87-93&author=B.+T.+Priestauthor=I.+M.+Bellauthor=M.+L.+Garcia&title=Role+of+hERG+potassium+channel+assays+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26atitle%3DRole%2520of%2520hERG%2520potassium%2520channel%2520assays%2520in%2520drug%2520development%26jtitle%3DChannels%26date%3D2008%26volume%3D2%26spage%3D87%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Kawai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span> </span><span class="NLM_article-title">A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1110</span><span class="NLM_x">–</span> <span class="NLM_lpage">1116</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2011&pages=1110-1116&author=Y.+Kawaiauthor=S.+Tsukamotoauthor=J.+Itoauthor=K.+Akimotoauthor=M.+Takahashi&title=A+risk+assessment+of+human+ether-a-go-go-related+gene+potassium+channel+inhibition+by+using+lipophilicity+and+basicity+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DY.%26aulast%3DTsukamoto%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DJ.%26aulast%3DAkimoto%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DM.%26atitle%3DA%2520risk%2520assessment%2520of%2520human%2520ether-a-go-go-related%2520gene%2520potassium%2520channel%2520inhibition%2520by%2520using%2520lipophilicity%2520and%2520basicity%2520for%2520drug%2520discovery%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2011%26volume%3D59%26spage%3D1110%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Liddle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douault, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elwes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garton, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayhow, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavens, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, A. G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez-Molina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skone, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smithers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weingarten, G. G.</span><span> </span><span class="NLM_article-title">Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6188</span><span class="NLM_x">–</span> <span class="NLM_lpage">6194</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6188-6194&author=J.+Liddleauthor=F.+L.+Atkinsonauthor=M.+D.+Barkerauthor=P.+S.+Carterauthor=N.+R.+Curtisauthor=R.+P.+Davisauthor=C.+Douaultauthor=M.+C.+Dicksonauthor=D.+Elwesauthor=N.+S.+Gartonauthor=M.+Grayauthor=T.+G.+Hayhowauthor=C.+I.+Hobbsauthor=E.+Jonesauthor=S.+Leachauthor=K.+Leavensauthor=H.+D.+Lewisauthor=S.+McClearyauthor=M.+Neuauthor=V.+K.+Patelauthor=A.+G.+S.+Prestonauthor=C.+Ramirez-Molinaauthor=T.+J.+Shipleyauthor=P.+A.+Skoneauthor=N.+Smithersauthor=D.+O.+Somersauthor=A.+L.+Walkerauthor=R.+J.+Watsonauthor=G.+G.+Weingarten&title=Discovery+of+GSK143%2C+a+highly+potent%2C+selective+and+orally+efficacious+spleen+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiddle%26aufirst%3DJ.%26aulast%3DAtkinson%26aufirst%3DF.%2BL.%26aulast%3DBarker%26aufirst%3DM.%2BD.%26aulast%3DCarter%26aufirst%3DP.%2BS.%26aulast%3DCurtis%26aufirst%3DN.%2BR.%26aulast%3DDavis%26aufirst%3DR.%2BP.%26aulast%3DDouault%26aufirst%3DC.%26aulast%3DDickson%26aufirst%3DM.%2BC.%26aulast%3DElwes%26aufirst%3DD.%26aulast%3DGarton%26aufirst%3DN.%2BS.%26aulast%3DGray%26aufirst%3DM.%26aulast%3DHayhow%26aufirst%3DT.%2BG.%26aulast%3DHobbs%26aufirst%3DC.%2BI.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DS.%26aulast%3DLeavens%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DH.%2BD.%26aulast%3DMcCleary%26aufirst%3DS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DV.%2BK.%26aulast%3DPreston%26aufirst%3DA.%2BG.%2BS.%26aulast%3DRamirez-Molina%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DT.%2BJ.%26aulast%3DSkone%26aufirst%3DP.%2BA.%26aulast%3DSmithers%26aufirst%3DN.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DWeingarten%26aufirst%3DG.%2BG.%26atitle%3DDiscovery%2520of%2520GSK143%252C%2520a%2520highly%2520potent%252C%2520selective%2520and%2520orally%2520efficacious%2520spleen%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6188%26epage%3D6194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><a href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf" class="extLink">http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.ich.org%2Ffileadmin%2FPublic_Web_Site%2FICH_Products%2FGuidelines%2FSafety%2FS2_R1%2FStep4%2FS2R1_Step4.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Adams, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelin, L. P.</span><span> </span><span class="NLM_article-title">Crystal structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide bound to d(CGTACG)2: implications for structure-activity relationships of acridinecarboxamide topoisomerase poisons</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=719-725&author=A.+Adamsauthor=J.+M.+Gussauthor=W.+A.+Dennyauthor=L.+P.+Wakelin&title=Crystal+structure+of+9-amino-N-%5B2-%284-morpholinyl%29ethyl%5D-4-acridinecarboxamide+bound+to+d%28CGTACG%292%3A+implications+for+structure-activity+relationships+of+acridinecarboxamide+topoisomerase+poisons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DA.%26aulast%3DGuss%26aufirst%3DJ.%2BM.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DWakelin%26aufirst%3DL.%2BP.%26atitle%3DCrystal%2520structure%2520of%25209-amino-N-%255B2-%25284-morpholinyl%2529ethyl%255D-4-acridinecarboxamide%2520bound%2520to%2520d%2528CGTACG%25292%253A%2520implications%2520for%2520structure-activity%2520relationships%2520of%2520acridinecarboxamide%2520topoisomerase%2520poisons%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2002%26volume%3D30%26spage%3D719%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Zang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, K. S.</span><span> </span><span class="NLM_article-title">DNA binding and alkylation by the “left half” of azinomycin B</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">14968</span><span class="NLM_x">–</span> <span class="NLM_lpage">14975</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi001998d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=14968-14975&author=H.+Zangauthor=K.+S.+Gates&title=DNA+binding+and+alkylation+by+the+%E2%80%9Cleft+half%E2%80%9D+of+azinomycin+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fbi001998d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi001998d%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DH.%26aulast%3DGates%26aufirst%3DK.%2BS.%26atitle%3DDNA%2520binding%2520and%2520alkylation%2520by%2520the%2520%25E2%2580%259Cleft%2520half%25E2%2580%259D%2520of%2520azinomycin%2520B%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D14968%26epage%3D14975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><div class="note"><p class="first last">Doxorubicin, a known intercalator, was titrated as a positve control for this assay. Structurally diverse Syk inhibitors were used as negative controls. See</p></div><span class="NLM_contrib-group">Northrup, A. B.; Altman, M. D.; Andresen, B. M.; Anthony, N. J.; Arrington, K. L.; Bhat, S.; Bienstock, C. E.; Black, C.; Burch, J.; Butcher, J. W.; Childers, K. K.; Cote, B.; Deschenes, D.; di Francesco, E.; Donofrio, A.; Ducharme, Y.; Dupont-Gaudet, K.; Ellis, J. M.; Fischer, C.; Fournier, J.-F.; Friesen, R.; Gauthier, J. Y.; Grimm, J. B.; Guay, D.; Guerin, D. J.; Haidle, A. M.; Jewell, J. P.; Kattar, S. D.; Li, C.; Lim, J.; Lee, S.; Liu, Y.; Machacek, M. R.; Maddess, M. L.; Miller, T. A.; O’Boyle, B. M.; Otte, R. D.; Peterson, S. L.; Petrocchi, A.; Reutershan, M. H.; Romeo, E. T.; Robichaud, J. S.; Schell, A. J.; Siu, T.; Smith, G. F.; Spencer, K. B.; Taoka, B. M.; Trotter, B. W.; Yang, L.; Woo, H. C.; Zhou, H.</span>Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, March 16–20, 2014; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>MEDI-36.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+B.+Northrup&author=M.+D.+Altman&author=B.+M.+Andresen&author=N.+J.+Anthony&author=K.+L.+Arrington&author=S.+Bhat&author=C.+E.+Bienstock&author=C.+Black&author=J.+Burch&author=J.+W.+Butcher&author=K.+K.+Childers&author=B.+Cote&author=D.+Deschenes&author=E.+di+Francesco&author=A.+Donofrio&author=Y.+Ducharme&author=K.+Dupont-Gaudet&author=J.+M.+Ellis&author=C.+Fischer&author=J.-F.+Fournier&author=R.+Friesen&author=J.+Y.+Gauthier&author=J.+B.+Grimm&author=D.+Guay&author=D.+J.+Guerin&author=A.+M.+Haidle&author=J.+P.+Jewell&author=S.+D.+Kattar&author=C.+Li&author=J.+Lim&author=S.+Lee&author=Y.+Liu&author=M.+R.+Machacek&author=M.+L.+Maddess&author=T.+A.+Miller&author=B.+M.+O%E2%80%99Boyle&author=R.+D.+Otte&author=S.+L.+Peterson&author=A.+Petrocchi&author=M.+H.+Reutershan&author=E.+T.+Romeo&author=J.+S.+Robichaud&author=A.+J.+Schell&author=T.+Siu&author=G.+F.+Smith&author=K.+B.+Spencer&author=B.+M.+Taoka&author=B.+W.+Trotter&author=L.+Yang&author=H.+C.+Woo&author=H.+Zhou&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DNorthrup%26aufirst%3DA.%2BB.%26jtitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="note"><p class="first last">All compounds tested to a top concentration of 406 μM DNA. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for further details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="note"><p class="first last">Ten of thirty compounds tested were negative in the UV–vis and bacterial mutagenicity assays.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="note"><p class="first last">A detailed account of the design principles applied to this scaffold redesign will be the subject of a future communication.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="note"><p class="first last">X-ray crystallograhpic data for the <i>C</i>-linked carboxamides will be detailed in a future communication.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="note"><p class="first last">We note that pyrazine <b>57</b> has not been tested in TA97a or the other strains used in the Ames bacterial mutagenicity assay.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="note"><p class="first last">The minimum surface area is the surface area of a sphere having a volume equal to the solvent-excluded volume of the molecule (computed from the Connolly molecular surface area and solvent-excluded volume properties).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i12"><a href="/doi/suppl/10.1021/jm5018169">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33131"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for synthesis of final compounds and intermediates, and descriptions of assays performed. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5018169/suppl_file/jm5018169_si_001.pdf">jm5018169_si_001.pdf (297.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5018169/suppl_file/jm5018169_si_002.csv">jm5018169_si_002.csv (2.07 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm5018169&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm5018169%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-4" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm5018169" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797c0bb839199f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
